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Antja-Voy Anthoneil Hartley 
REGULATION OF PROTEIN ARGININE METHYLTRANSFERASE 5 BY NOVEL 
SERINE 15 PHOSPHORYLATION IN COLORECTAL CANCER 
The overexpression of protein arginine methyltransferase 5 (PRMT5) is strongly 
correlated to poor clinical outcomes for colorectal cancer (CRC) patients. Previously, we 
demonstrated that PRMT5 overexpression could substantially augment activation of NF-
κB via methylation of arginine 30 (R30) on its p65 subunit, while knockdown of PRMT5 
showed the opposite effect on the transcriptional competence of p65. However, the 
precise mechanisms governing this PRMT5/NF-κB axis are still largely unknown.  We 
report a novel finding that PRMT5 is phosphorylated on serine 15 (S15) in response to 
interleukin-1β (IL-1β) stimulation. Overexpression of the serine-to-alanine mutant of 
PRMT5 (S15A-PRMT5), in either HEK293 cells or HT29, DLD1 and HCT116 CRC cells 
attenuated NF-κB activation compared to wild type (WT)-PRMT5, confirming that S15 
phosphorylation is critical for the activation of NF-κB by PRMT5. Furthermore, we found 
that overexpression of S15A-PRMT5 mutant attenuated the expression of a subset of 
NF-κB target genes through decreased p65 occupancy at their respective promoters. 
Importantly, the S15A-PRMT5 mutant also reduced IL-1β-induced methyltransferase 
activity of PRMT5 as well as its ability to form a complex with p65. Finally, we observed 
that the S15A-PRMT5 mutant diminished the growth, migratory and colony-forming 
abilities of CRC cells compared to the WT-PRMT5. Collectively, our findings provide 
strong evidence that novel phosphorylation of PRMT5 at S15 is critical to its regulation of 
NF-κB and plays an essential role in promoting the cancer-associated functions exerted 
by the PRMT5/NF-κB axis. Therefore, development of inhibitors to block phosphorylation 
of PRMT5 at S15 could become a potential novel therapeutic approach to treat CRC. 
  
Tao Lu, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
1.1 Colorectal cancer 
1.1.1 Risk factors, progression and common genetic causes 
As the third leading cause of cancer-related deaths globally, colorectal cancer 
(CRC) is expected to be responsible for an estimated 1.1 million deaths by 2030 (Ferlay 
et al., 2019). Several modifiable risk factors are attributable to a person’s likelihood of 
developing CRC including smoking, a low-fiber high-fat diet, alcohol consumption, 
obesity and diabetes. Additional risk factors include increasing age, heredity conditions 
such as polyposis and hereditary nonpolyposis lesions as well as a history of ulcerative 
colitis and inflammatory bowel disease (Johnson et al., 2013).  
CRC patients often present with a broad spectrum of neoplasms that arise 
from the sequential accumulation of genetic and epigenetic aberrations (Hong, 2018). 
Together, these aberrations underlie the etiological basis of the progression of benign 
adenomas to malignant carcinomas in a well-defined model known as the adenoma-to-
carcinoma sequence of CRC development (Figure 1) (Fearon et al., 1990). Most 
sporadic CRCs arise through this sequence which is most commonly initiated by 
inactivating mutations of the adenomatous polyposis coli (APC) tumor suppressor gene 
during the formation of the earliest lesions known as aberrant crypt foci (L. Zhang et al., 
2017). Most APC mutations result in the synthesis of a truncated protein due to 
frameshift or nonsense mutations, which occur in approximately 30%–70% of sporadic 
CRCs (Schell et al., 2016). As a critical component and negative regulator of the 
canonical Wnt signaling pathway, APC mainly exerts its tumor suppressor activity by 
blocking the G1 to S transition in the cell cycle thereby limiting excessive proliferation of 
colonic epithelial cells by inducing degradation of β-catenin (Heinen et al., 2002). 
Deregulation of Wnt signaling and accumulation of nuclear β-catenin leads to unchecked 
expansion of epithelial cells (Schneikert et al., 2006). This excessive proliferation is a 
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hallmark characteristic of early adenomas which are defined as benign tumors observed 
less than 1 cm in size with tubular or tubulovillous histology (Fleming et al., 2012).  
Activation of the oncogene KRAS signifies the second step in the progression 
towards advanced stages of CRC. KRAS mutations are found in approximately 50% of 
CRC cases and have become an important predictive marker for the effectiveness of 
certain treatments modalities (Andreyev et al., 2001; Verdaguer et al., 2017). Aberrant 
KRAS activation is also a hallmark of the late adenoma stage (>1 cm in size, villous 
histology), in which tumor cells are still confined within the epithelial layer but tend to 
show disorganized growth and develop into highly dysplastic tumors. The most 
commonly observed mutations for KRAS are substitutions at codons 12 and 13 (G12D, 
G13D, respectively) both located in exon 2 and occur in nearly 60% of colon ademonas 
(Jones et al., 2017). These activating mutations are an integral step in achieving 
constitutive activation of the mitogen activated protein kinase (MAPK) pathway which 
leads to unchecked proliferation, survival, angiogenesis, invasion, and metastasis of 
malignant colon epithelial cells via upregulation of associated target gene products 
(Hatzivassiliou et al., 2013). Sustained activation of MAPK signaling may also occur via 
a V600E point mutation in BRAF which leads to constitutive activation (Morkel et al., 
2015).  
Further malignant transition towards the carcinoma stage is accompanied by loss 
of heterozygosity (LOH) of the long arm of chromosome 18 (18q) and short arm of 
chromosome 17 (17p) (Pino et al., 2010). 18q/17p LOH, along with concomitant 
mutational inactivation of the tumor suppressor TP53 gene, constitutes a critical final 
step in the development of malignant colorectal carcinomas (C.-Z. Zhou et al., 2004). 
These tumors are characterized by their ability to invade the surrounding tissues and 
eventually metastasize to distal organs such as the liver. Additionally, several studies 
have endeavored to elucidate the prognostic value of the TP53 mutation status by 
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demonstrating a link between these mutations and lymphatic invasion in proximal CRC 
(Russo et al., 2005). Patients with mutant TP53 also appear to be more chemo-resistant 
with poorer prognosis compared to those with wild-type TP53 (Iacopetta, 2003).  
 
1.1.2 Epigenetic causes  
The development of CRC has also been linked to the accumulation of multiple 
epigenetic alterations (Baretti et al., 2018). Unlike genetic mutations, epigenetic 
modifications consist of heritable changes in gene expression without DNA sequence 
changes and are intrinsically reversible by nature. Moreover, the reversibility of these 
modifications makes them attractive molecular targets for anticancer therapeutic 
interventions (Kelly et al., 2010; Okugawa et al., 2015). Assessment of the epigenetic 
landscape of CRC reveals that virtually all cases harbor abnormal changes in DNA 
methylation and histone modifications (Irizarry et al., 2009). DNA methylation for 
instance, constitutes one of the first recognized epigenetic alterations in CRC, where 
global DNA hypomethylation and discrete, systematic hypermethyation are frequently 
observed. More precisely, global DNA hypomethylation, which mainly takes place on 
cytosine guanine (CpG) dinucleotides within pericentromeric regions, is primarily 
associated with widespread oncogene activation and increased genomic instability. 
Discrete DNA hypermethylation however, typically occurs at CpG dinucleotide-dense 
regions, called CpG islands. These CpG islands are found within the promoters of many 
tumor suppressor genes, resulting in transcriptional silencing (e.g., APC). However, 
other reports have shown that this hypermethylation also exists within the first 
exonic/intronic regions of several other genes involved in DNA repair, apoptosis, 
proliferation, angiogenesis, adhesion, and invasion [e.g., Secreted frizzled related 
protein 5 (SFRP5), Insulin-like growth factor 2 (IGF2) and Cyclin-dependent kinase 
inhibitor 2A (p16INK4a/CDKN2A)] (Irizarry et al., 2009; Jia et al., 2013). Many of these 
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changes occur gradually and begin early in the process of colorectal carcinogenesis 
(Luo et al., 2014).  
Furthermore, abnormal histone methylation and acetylation have been shown to 
be highly recurrent and serve as important biomarkers to predict clinical outcome for 
CRC patients (Vaiopoulos et al., 2014). For instance, reduced levels of H3K9me3 and 
H4K20me3 found within circulating nucleosomes are strongly correlated with poor CRC 
patient outcome. Conversely, high H4K20me3 and H3K9me3 but low nuclear expression 
of H3K4me3 are usually associated with a better prognosis for early-stage CRC patients 
(Benard et al., 2014; Tamagawa et al., 2012). Interestingly, many of these post-
translational marks coincide with repression and activation of key tumor suppressors and 
oncogenes, respectively (T. Huang et al., 2017; Kodach et al., 2010). For example, DNA 
hypermethylation-mediated silencing of several Wnt pathway inhibitors (e.g., AXIN1, 
AXIN2, WTX, RNF43) has been suggested as a main contributor to hyperactivation of 
the Wnt pathway (Galamb et al., 2016). Thus, epigenetic regulation represents another 
critical mechanism by which cancer cells achieve tumor-promoting transcriptional 
changes in the absence of genetic mutations. With such profound regulatory potential, it 
is not surprising that deregulation of certain key epigenetic modulators gives rise to 
many of the malignant processes commonly seen in CRC (T. Huang et al., 2017). 
Indeed, changes in the expression or activity levels of several classes of epigenetic 
modulators have been linked to CRC, particularly methyltransferases and histone 
deacetylases (Vaiopoulos et al., 2014). 
These studies collectively highlight the complexity and heterogeneity of CRC, 
further underscoring the need to identify new biomarkers and therapeutic targets for 





Figure 1: Schematic of the adenoma-to-carcinoma sequence of CRC (Walther et al., 
2009). The temporal order in which changes in key genes may affect the progression of 
CRC is shown above the histological stages of disease. Briefly, this sequence is initiated 
by inactivating mutations of the APC tumor suppressor gene during the formation of the 
earliest lesions, aberrant crypt foci (ACF; not shown). These ACFs evolve into early 
adenomas which are defined as benign growths less than 1 cm in size with tubular or 
tubulovillous histology. Transition to a late adenoma stage is achieved by activating 
mutations in the KRAS oncogene. Late adenomas are greater than 1 cm in size, still 
confined within the epithelial layer and tend to show disorganized growth and dysplasia. 
Finally, loss of heterogeneity (LOH) of the long arm of chromosome 18q and short arm 
of chromosome 17p as well as inactivating mutations of the TP53 gene increase 
chromosomal instability, which are crucial events in the transition of tumors cells into 
























1.1.3 Current treatment options and limitations 
With important advances in early screening, the 5-year survival rate (≥60%) for 
patients diagnosed at early stages of CRC has made tremendous leaps over the years 
(Simon, 2016). For these patients, surgery along with adjuvant chemotherapy are the 
mainstay treatment for resectable tumors.  Unfortunately, more than half of patients 
present with metastatic CRC (mCRC) at the time of diagnosis in which case the outlook 
is dismal with a 5-year survival rate of only 10% (Nakayama et al., 2013). For patients 
with mCRC, surgery is usually not an option and chemotherapeutic intervention is the 
only means of improved survival. Before the advent of combinatorial chemotherapeutic 
regimens, the standard of care for unresectable mCRC was first-line monotherapy with 
5-fluorouracil, a cytotoxic agent that exerts its anticancer effects by blocking DNA 
synthesis through inhibition of thymidylate synthase. Today, combination regimens such 
as FOLFIRI (combination of 5-FU, leucovorin, and irinotecan) and FOLFOX 
(combination of 5-FU, leucovorin, and oxaliplatin) have now become the cornerstone of 
anti-cancer therapy (Benson et al., 2013). The use of targeted therapies has also 
become increasingly important and several monoclonal antibodies against vascular 
endothelial growth factor (VEGF; bevacizumab) and epidermal growth factor receptor 
(EGFR; cetuximab) have been incorporated into the routine clinical care of mCRC 
patients (Saltz et al., 2008; Van Cutsem et al., 2011). Notably, the mutational status of 
KRAS is a major predictor of resistance to cetuximab therapy where patients with 
mutated KRAS (G12D) have a worse prognosis (Arrington et al., 2012). Another targeted 
agent which is used after other lines of therapy have failed is regorafenib, a multikinase 
inhibitor that affects several signaling pathways including VEGF signaling (Goel, 2018).    
With the growing global burden of a high incidence rate, prevention and 
treatment of CRC remains a significant public health challenge. Unfortunately, due to the 
extreme aggressiveness and complex molecular heterogeneity of these tumors as well 
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the emergence of therapeutic resistance, the afore-mentioned treatment modalities are 
hardly curative, necessitating treatment for many years (Cidón, 2010). Moreover, 
progress in developing new treatment options for CRC has been relatively static over the 
past decade, underscoring the urgent need to better understand molecular mechanisms 
that drive CRC which can be translated into clinical utility.  
The nuclear factor-kappa B (NF-κB) signaling pathway serves as a central 
coordinator of immune and inflammatory responses and has been implicated in driving 
several hallmark tumorigenic processes (T. Liu et al., 2017; Xia et al., 2014). Importantly, 
constitutive activation of NF-κB is also frequently observed in CRC and has garnered 
increasing attention as a potential therapeutic target (Vaiopoulos et al., 2013). The 
following sections discuss the current evidence linking NF-κB hyperactivity to CRC 
initiation and progression, lending credence to targeting this important pathway as a 
promising treatment strategy for CRC.  
 
1.2 NF-ĸB signaling and its role in CRC 
1.2.1 Overview of NF-ĸB signaling pathways 
The family of NF-κB transcription factors consists of five members, namely, p65 
(RelA), RelB, c-Rel, p105/p50 (NF-κB1), and p100/52 (NF-κB2). These proteins form 
distinct homo- or heterodimeric complexes, with the p65/p50 heterodimer being the most 
prominent (Dolcet et al., 2005). Notably, both p50 and p52 are produced by proteasomal 
processing of their precursors p105 and p100, respectively. Although structurally 
diverse, all NF-κB family members share a highly conserved domain – the N-terminal 
Rel homology domain (RHD), which is required for dimerization, DNA binding, 
interaction with the inhibitors of NF-κB (IκBs) and nuclear translocation (Karin et al., 
2000). By contrast, the C-terminal transactivation domain (TAD) is conserved only 
among the Rel proteins, including p65 (RelA), RelB, and c-Rel and confers 
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transcriptional competence (Karin et al., 2000). In unstimulated cells, NF-κB dimers are 
latent and sequestered in the cytoplasm via association with the inhibitory IκB family of 
proteins. The IκB family also consists of several members (IκBα, IκBβ, IκBγ, IκBε, Bcl-3, 
p100, and p105) with IκBα and IκBβ being known for their prominent roles in binding to 
NF-κB heterodimers, effectively blocking their nuclear localization. All members of the 
inhibitory IκB complexes including p100 and p105 are characterized by the presence of 
ankyrin repeat domains (ANK) in their structure, which are purported to mask the nuclear 
localization signals (NLS) of NF-κB heterodimers, thus sequestering them in the 
cytoplasm (Karin et al., 2000). A detailed depiction of the domain architecture of various 













Figure 2: Schematic of the NF-ĸB family members (Hartley et al., 2018). The NF-B 
family members are defined by the N-terminal Rel Homology Domain (RHD), which is 
responsible for DNA binding and dimerization. All except p52 and p50 contain a 
Transactivation Domain (TAD), which confers positive regulation of gene expression. 
p52 and p50 also contain glycine rich regions (GRR), which are necessary for their 
proteolytic cleavage and ankyrin repeats (ANK) similar to those found in IB family of 
inhibitor proteins. Additionally, RelB contains a leucine zipper motif (LZ). Other 
abbreviation: DD, dimerization domain. Permission to use all or part of this published 













Activation of NF-κB can be classified into two distinct pathways, commonly 
referred to as the canonical and non-canonical pathways (Figure 3). In both pathways, 
NF-κB heterodimers are retained in the cytoplasm by IκB proteins under resting states. 
In general, NF-κB can be activated by a diverse array of stimuli that lead to IB kinase 
(IKK)-dependent phosphorylation, polyubiquitination, and subsequent proteasome-
mediated degradation of IκB proteins, a common regulatory step for both pathways. The 
liberation of NF-κB subunits then allows them to translocate to the nucleus, where they 
can bind to cognate κB sites in specific promoter regions to activate target gene 
expression (Shih et al., 2011; S.-C. Sun, 2017).  
The canonical pathway, which primarily regulates the transcription of genes 
involved in inflammation, innate immunity and cell survival, is typically simulated by 
factors such as tumor necrosis factor α (TNFα), interleukin 1 (IL-1), or lipopolysaccharide 
(LPS), leading to IKK activation. The IKKβ subunit of the IKK complex phosphorylates 
serine residues in the signal responsive region (SRR) of IĸBα, leading to its 
ubiquitination and subsequent proteasomal degradation. No longer sequestered by IĸBα, 
the p65/p50 heterodimer is now free to translocate to the nucleus to induce transcription 
of target genes (Greten & Karin, 2004; Hayden et al., 2004). By contrast, the non-
canonical pathway, which is mainly implicated in the regulation of B-cell maturation, 
humoral immunity and lymphoid organ development, depends on NF-ĸB-inducing kinase 
(NIK)-induced activation of IKKα and is typically simulated by ligands such as cluster of 
differentiation 40 ligand (CD40L), LPS, and B-cell activating factor (BAFF). In this 
pathway, p100/RelB complexes are retained in an inactive state in the cytoplasm. 
Signaling through a small subset of receptors such as lymphotoxin-β receptor (LTβR), 
CD40, and BAFF receptor 3 (BR3) activates NIK which is rapidly recruited to 
phosphorylate IKKα. The net effect is phosphorylation and ubiquitination of p100, and its 
subsequent proteasomal processing to p52. This signaling cascade creates a 
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transcriptionally competent RelB/p52 complex that can translocate to the nucleus and 
initiate target gene expression (Bonizzi et al., 2004; S.-C. Sun, 2017).  
Finally, although abnormal activation of both arms of this signaling pathway is 
involved in tumorigenesis and is known to play critical roles in tumor growth, 
progression, and therapeutic resistance, the canonical NF-κB pathway has been more 
extensively studied and implicated in solid tumors such as CRC (Hoesel et al., 2013). On 
the other hand, the non-canonical pathway has been documented as primarily playing a 
role in hematological malignancies such as multiple myeloma (Imbert et al., 2017). Since 
CRC is the main cancer of interest in this study, discussion in the subsequent sections 

































Figure 3: Schematic of the canonical and non-canonical NF-ĸB pathways (Hartley et al., 
2018). The canonical pathway (left) is induced by most physiological NF-ĸB stimuli and 
is represented here by TNF, IL-1 and LPS signaling. Stimulation of the corresponding 
receptor leads to the IKK complex activation comprised of two catalytic subunits, IKKα 
and IKKβ as well as the regulatory IKK or NEMO subunit. IB is then phosphorylated 
in an IKKβ- and NEMO-dependent manner, which results in its polyubiquitination and 
subsequent degradation. The liberated p65/p50 heterodimer undergoes nuclear 
translocation where it engages in target gene transcriptional activation. The non-
canonical pathway (right) is induced by a more selective family of molecules, such as 
LPS, CD40L, BAFF and lymphotoxin- (LT-). Upon activation, p100 processing 
depends on NIK, which triggers IKKα-mediated phosphorylation of p100, leading to 
partial processing of p100 and the generation of transcriptionally active p52/RelB 












1.2.2 NF-κB and IL-1β signaling in CRC initiation and progression 
Over the past decade, NF-κB has emerged as a master regulator of inflammatory 
responses and tumor development. In CRC especially, NF-κB has been shown to be 
constitutively activated in nearly 60–80% of patient tumors (S. Wang et al., 2009). 
Constitutive NF-κB activity seems to play a critical role in virtually all the hallmarks of 
cancer and contributes to both tumor initiation and progression. This is largely 
accomplished by its upregulation of the expression of a diverse array of target genes, 
many of which mediate malignant processes such as cellular proliferation (e.g., cyclin 
D1), anti-apoptosis [(e.g., survivin, B-cell lymphoma 2 (Bcl-2), X-linked inhibitor of 
apoptosis protein (XIAP), inhibitor of apoptosis protein 1 (IAP1)], angiogenesis [(e.g., 
vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), cyclooxygenase 2 
(COX2)], and metastasis [(e.g., matrix metallopeptidase 9 (MMP9), intercellular 
adhesion molecule 1 (ICAM-1)] (Hassanzadeh, 2011).  
Furthermore, a wealth of evidence supports the role of NF-κB-mediated chronic 
inflammation as one of the key etiologic factors in CRC development. In fact, a classic 
example is inflammatory bowel diseases (IBDs), in which constitutive NF-κB activation 
has been shown to significantly increase the risk of CRC development in patients with a 
number of years of active disease (Atreya et al., 2008; Eaden et al., 2001).  The 
interconnection between inflammation and cancer was initially proposed by Virchow in 
the mid-nineteenth century when he hypothesized that cancer arose at regions of 
chronic inflammation brought about by irritants and tissue injury (Balkwill et al., 2001). 
IBD is associated with persistent NF-κB activation in cells such as the myeloid and 
epithelial cells located within the colonic mucosa. This results in a sustained 
inflammatory process in the gut mucosa that promotes cell survival and tumorigenesis 
(Greten, Eckmann, et al., 2004). As such, aberrant NF-κB activation was shown to bring 
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about the malignant transformation of colon epithelial cells via its transcriptional 
upregulation of pro-inflammatory cytokines, chemokines and growth factors (Neurath et 
al., 1998). Once these inflammation-driven sporadic tumors are formed, elevated NF-κB 
activity is further achieved by the induction of a local network of cytokines/chemokines 
and immune/inflammatory cell infiltration into affected sites (Greten, Eckmann, et al., 
2004). Among these cytokines and chemokines, are a host of NF-κB target genes such 
as TNF-α and IL8, the upregulation of which has been shown to strongly correlate with 
CRC severity and poor prognosis (Mager et al., 2016). The continuous release of 
cytokines and growth factors by both tumor and immune cells within the tumor 
microenvironment results in a feed-forward, prolonged retention of nuclear NF-κB. 
Ultimately, this sustained NF-κB-mediated inflammation stimulates tumor proliferation 
and invasiveness, amplifying the overall metastatic potential of CRC cells (Figure 4) 
(Cooks et al., 2013). As expected, inhibition of the NF-κB pathway and subsequent 
downregulation of relevant target genes has been shown to attenuate the formation of 
tumors in a CRC mouse model (Greten, Eckmann, et al., 2004). 
In addition to its pro-inflammatory role, NF-κB has also been widely implicated in 
mediating chemoresistance through the activation of a multitude of anti-apoptotic and 
pro-survival target genes (Godwin et al., 2013).  For instance, several studies have 
shown that aberrant activation of NF-κB mediates 5-FU resistance in CRC cells, which 
constitutes one major reason for the failure of mCRC treatment (Konishi et al., 2006; Z. 
Wang et al., 2018). Unsurprisingly, NF-κB inhibitors such as resveratrol, SN50 and 
quinacrine which block the transcriptional activity, nuclear translocation and DNA binding 
of p65, respectively, when used in combination with chemotherapeutics 5-fluorouracil 
and oxaliplatin, have been shown to synergistically mitigate CRC cell growth (Buhrmann 
et al., 2018; Jani et al., 2010; Z. Wang et al., 2018). In another study, combination of 
irinotecan with NF-κB-targeting thymoquinone was shown to increase sensitivity of CRC 
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cells to irinotecan (M. C. Chen et al., 2017). Taken together, these findings implicate NF-
κB as an important therapeutic target in CRC.          
IL-1β is a pleiotropic pro-inflammatory cytokine abundantly secreted at tumor 
sites primarily by epithelial and inflammatory cells, mediating the induction of a local 
network of cytokines/chemokines and cell infiltration into affected sites (Apte et al., 
2006). This in turn significantly affects the process of tumorigenesis by modulating tumor 
growth and invasiveness, tumor-mediated angiogenesis, and also the patterns of tumor-
host interactions in the reactive tumor microenvironment (Apte et al., 2006; Carmi et al., 
2013). Importantly, a high IL-1β concentration within the tumor microenvironment has 
been associated with a more malignant tumor phenotype and in CRC, is shown to 
promote the invasiveness of colon tumor cells (Li et al., 2012). The tumor-promoting role 
of IL-1β in the cancer microenvironment is further augmented by the fact that it serves as 
a potent inducer of NF-κB activity (Hai Ping et al., 2016). In the proposed work, we have 
established a critical link between IL-1β-mediated PRMT5 phosphorylation and 
enhanced NF-κB activation, which is of potentially enormous biological significance. We 
propose that activation of this PRMT5/NF-κB signaling node by IL-1β secreted by cells in 
the tumor microenvironment could concertedly promote inflammation-associated tumor 









Figure 4: Constitutive activation of NF-B promotes inflammation and CRC progression 
(Hartley et al., 2018). Bacteria and various “irritants” of the gut cause tissue injury and 
inflammation, leading to excessive production of pro-inflammatory cytokines. These 
cytokines bind to cell surface receptors of colon epithelial cells, resulting in NF-B 
activation in these cells. NF-B activation in colon epithelial cells increases cell 
proliferation and survival via upregulation of proliferative and pro-survival NF-B target 
genes, thus contributing to the malignant transformation of these cells. Activation of NF-
B in inflammatory cells from the tumor microenvironment also contributes to CRC 
development by inducing expression of cytokines, chemokines and growth factors. This 
leads to constitutive activation of NF-B in tumor cells, which in turn, release numerous 
factors that sustain the ongoing paracrine inflammatory process between the tumor 
microenvironment and tumor cells and the autocrine loop between tumor cells. 
Hyperactive NF-B in tumor cells promotes expression of diverse NF-B target genes, 
including cytokines, chemokines and growth factors, as well as genes that are 
associated with metastasis, such as those promoting proliferation, migration, 
angiogenesis, adhesion, and invasion of tumor cells. Permission to use all or part of this 






1.2.3 Limitations of current NF-ĸB inhibitors 
Because of the multitude of cancer-initiating and malignant processes affected by 
NF-κB signaling, much effort has been made by the pharmaceutical industry to develop 
inhibitors to target this pathway. To date, over 750 inhibitors have been identified, 
ranging from small molecules, natural compounds and their derivatives to small 
DNA/RNAs, engineered polypeptides and viral proteins (Gilmore et al., 2006). Notably, 
development of several of these inhibitors is targeted towards impeding one or several 
nodes along the canonical NF-κB signaling pathway. For instance, the development of 
inhibitors based on blockade of IKK or proteasomal degradation of IĸBα has been amply 
described (Llona-Minguez et al., 2013). Certain phytochemicals such as curcumin, green 
tea extract, ginseng and resveratrol have been shown to inhibit IKK activity (Gonzales et 
al., 2008; Gupta et al., 2010; Su et al., 2006). Proteasome inhibitors (e.g., bortezomib), 
which have generally yielded more success, act by blocking the degradation of IκBα to 
enhance cytoplasmic retention of NF-κB heterodimers (Adams, 2002). However, very 
few documented reports exist to support their efficacy in triggering apoptosis when used 
as a monotherapy in cancer (Hartley et al., 2018). 
Unfortunately, the vast majority of these inhibitors have not yet been approved 
for clinical applications in cancer.  Moreover, several molecules including non-steroidal 
anti-inflammatory drugs (NSAIDs) were found to only collaterally limit NF-κB activity and 
thus lack selectivity for cancer cells. Besides, there is a certain degree of reluctance 
associated with direct and prolonged inhibition of NF-κB, which is inherently complicated 
and challenging on many levels. First, NF-κB cooperates with a multitude of other 
signaling molecules and pathways, many of which directly interact with NF-κB subunits 
or affect NF-κB target genes in normal cellular processes. These molecules may or may 
not themselves be contributors to the cancer process and thus, disruption of these 
critical signaling nodes of crosstalk using broad-spectrum inhibitors could potentially 
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yield undesirable secondary effects. Second, NF-κB is also an essential player in the 
immune response against cancer. Thus, global and prolonged immunosuppression via 
direct or nonspecific NF-κB inhibition is likely to have deleterious effects on patients due 
to associated immune-related toxicities (Baud et al., 2009). To further complicate 
matters, some standard chemotherapeutic agents such as doxorubicin, irinotecan and 5-
FU can inadvertently activate the NF-κB pathway via induction of proinflammatory 
cytokines (eg IL-1β, TNFα) and cellular stressors (e.g., ROS) or by activating DNA-repair 
mechanisms (Bednarski et al., 2008; W. Wang et al., 2017). Theoretically, an ideal NF-
κB inhibitor should therefore prevent NF-κB activation and be more selective in 
destroying malignant cells with little to no adverse effects on other signaling pathways or 
interference with NF-κB’s physiological roles in immunity, inflammation, and cellular 
homeostasis. 
Although we may be a long way from developing the most effective and least 
toxic anti-NF-ĸB agent, a more indirect yet cancer-selective inhibition of NF-κB signaling 
may be achieved by first identifying key proteins that are frequently deregulated in 
cancer and are known to activate this pathway in tumor cells. These proteins can then 
be selectively targeted in cancer cells in lieu of broad-spectrum inhibition of NF-κB, given 
its pleiotropic and ubiquitous functions. This approach has been used with some 
success which involves the use of inhibitors against upstream regulators of NF-κB, such 
as PI3K and mTOR (Ahmad et al., 2013). In this respect, we previously established a 
connection between overexpression of PRMT5 which is frequently observed in CRC, 
and enhanced activation of NF-κB and its target genes (Prabhu et al., 2017; Wei et al., 
2013). Importantly, the work described in this thesis demonstrates a novel phospho-
dependent relationship between PRMT5 and NF-κB in CRC. Disruption of the 
PRMT5/NF-κB signaling axis by blocking phosphorylation of PRMT5 may thus serve to 
broaden options for therapeutic intervention. The next sections provide an overview of 
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PRMT5, including its general biological roles, specific contribution to cancer as well as 
insights into the regulation of its activity.   
 
1.3 PRMT5 
1.3.1 Overview of PRMT superfamily members and arginine methylation  
Post-translational modifications (PTMs) have evolved as focal points of signal 
transduction. They are crucial to initiating and augmenting signaling cascades by fine-
tuning the function of the molecules they alter (Deribe et al., 2010).  Moreover, many 
PTM events may in part underlie the transcriptional and epigenetic-driven changes in 
gene expression that lie at the heart of various normal cellular requirements. 
Unsurprisingly, in pathological states, the enzymes that catalyze the addition and 
removal of PTMs are frequently dysregulated and have emerged as major drug targets 
for a variety of diseases, including cancer. 
Arginine methylation continues to garner intense interest as a key PTM, largely 
due to its role as a regulator of both histone and non-histone proteins involved in diverse 
cellular processes. These processes include splicing, RNA processing, transcription, 
development, DNA damage repair, proliferation, and signal transduction (Bedford et al., 
2009). The result of arginine methylation is the addition of methyl groups to the 
guanidino nitrogen atoms of arginine residues in proteins; the complexity is further 
augmented by the addition of either one or two methyl groups. Specifically, there are 
three main types of arginine methyl marks: ω-NG, monomethylarginines (MMA); ω-
NG,NG-asymmetric dimethylarginines (ADMA); and ω-NG,N′G-symmetric 
dimethylarginines (SDMA) (Bedford et al., 2009). These marks are deposited by the 
family of protein arginine methyltransferases (PRMTs) that consists of nine members, 
classified by which mark they catalyze. For instance, type I, II and III PRMTs all catalyze 
the formation of MMA intermediates, while type I PRMTs (PRMT1, 2, 3, 4, 6 and 8) also 
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catalyze the production of ADMA. Meanwhile, type II PRMTs (PRMT5 and PRMT9) 
catalyze the formation of SDMA. PRMT7 was described as exhibiting type III enzymatic 
activity due to its preferential formation of MMA on histones, its only known substrates 
(Figure 5) (Zurita-Lopez et al., 2012). More recently, a type IV enzyme which remains to 
be fully characterized was identified only in yeast as monomethylating the internal (or δ) 
guanidino nitrogen atom. Notably, however, no homolog of this enzyme has been 
identified in higher eukaryotic organisms (Zobel-Thropp et al., 1998). 
The majority of PRMT substrates harbor conserved glycine (G)- and R-rich 
(GAR) motifs. A notable exception is PRMT4 (CARM1) which methylates arginine 
residues within proline and glycine-rich (PGM) motifs (Bedford et al., 2009; Gayatri et al., 
2016). Others such as PRMT5, can methylate arginine residues located within both GAR 
and PGM motifs (Branscombe et al., 2001; Cheng et al., 2005). In addition to these 
substrate recognition motifs, the nine members of human PRMT family share a highly 
homologous S-adenosylmethionine (SAM)-dependent methyltransferase domain known 
as the Rossman fold, which serves as the catalytic core. However, the human PRMT 
family members also have divergent structural motifs (Figure 6). For instance, PRMT2, 
PRMT3, PRMT4, PRMT5 and PRMT9 all have N-terminal motifs preceding the catalytic 
domain. In PRMT2 and 3, a SRC Homology 3 Domain (SH3) domain and zinc-finger 
domain (ZnF) precedes the Rossman fold, respectively.  Meanwhile, a pleckstrin 
homology (PH), triosephosphateisomerase (TIM) barrel and tetratricopeptide (TRP) motif 
precedes the catalytic domain in PRMT4, 5 and 9, respectively (Cheng et al., 2005; 
Schapira et al., 2014). Generally speaking, these additional N-terminal motifs have been 
purported to regulate PRMTs in terms of their substrate recognition or complex formation 
and thus serve to contribute to their nonredundant roles in different biological processes 
(Stephen Antonysamy et al., 2012; Kozbial et al., 2005).  
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Although MMA, ADMA and SDMA all potentially have different functional 
consequences, the overall main effect of arginine methylation is alteration of protein-
protein, protein-DNA, and protein-RNA interactions by the methylated protein 
(Dolzhanskaya et al., 2006). This is evidenced in the structural effects conferred by this 
PTM. For example, each arginine residue of a protein has five potential hydrogen-bond 
donors which interact with the hydrogen-bond acceptors of its interacting partners. The 
addition of a methyl group therefore sterically affects these interactions by providing 
increased hydrophobicity without changing the overall charge of the residue. 
Furthermore, methylation adds to the overall mass of the protein as indicated by a mass 
shift of ∼14 Da (MMA) or ∼28 Da (ADMA or SDMA). Ultimately, this results in either 
positive or negative effects on the interaction of the methylated proteins with other 
molecules (Blanc et al., 2017). 
Interestingly, it also not uncommon for type I and II PRMTs to share the same 
substrates with differential outcomes. For example, a recent study from our lab 
demonstrated that PRMT5-mediated symmetric methylation of p65 at R30 (R30me2s) 
positively regulated the DNA-binding ability of p65 and its capacity to drive 
transcriptional activation of target genes (Wei et al., 2013). Moreover, predicted 
modelling revealed a stabilizing effect of R30me2 through van der Waals contacts that 
indirectly increased the affinity of p65 for DNA. Conversely, Reintjes et al (2016) 
reported a mechanism by which TNFα-induced asymmetric dimethylation of p65 by 
PRMT1 (R30me2a) resulted in impaired binding of NF-κB to gene promoters (Reintjes et 
al., 2016). Thus, in this case, ADMA and SDMA marks on p65 may potentially represent 
a specific on/off switch mechanism for moderating cytokine-induced NF-κB responses.  
Intriguingly, a similar phenomenon was observed with another transcription factor, E2F-
1, whereby competitive PRMT5- and PRMT1-catalyzed SDMA and ADMA marks, 
respectively had differential effects on its DNA-binding and transactivating potential (S. 
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Zheng et al., 2013). This dichotomy suggests a nuanced and likely context-specific 
structural effect of ADMA versus SDMA moieties on a given substrate protein. Arginine 
methylation has also been shown to affect other critical aspects of a protein, including its 
stability, subcellular localization and enzymatic activity. For instance, methylation of 
CARM1-mediated methylation of SRC-3 was shown to enhance its turnover whereas 
methylation of RNA helicase A is required for its nuclear import (Naeem et al., 2007; 
Smith et al., 2004). Undoubtedly, the above findings are only a fraction of the roles of 
arginine methylation in diversifying the functions of the proteome. It is possible that even 
more roles will be uncovered in the near future, particularly as it relates to the 
involvement of this PTM in the pathogenesis of various diseases, including cancer.  
 
1.3.2 PRMT5: Biological roles and contribution to cancer 
PRMT5 is the main type II methyltransferase and is responsible for 95 percent of 
the symmetric dimethylation observed in cells. In addition to histones, PRMT5 
methylates a wide variety of non-histone substrates such as Sm proteins, transcription 
factors (e.g., p65, p53) and signaling effector proteins (e.g., RAF). Importantly, these 
methylation events impact several biological processes, including transcriptional control, 
proliferation, DNA damage response and repair, splicing, signal transduction, 
differentiation and development, among others (Stopa et al., 2015). 
1.3.2A General biological roles of PRMT5  
Before its methyltransferase activity was biochemically characterized, PRMT5 
was first discovered as a Janus kinase 2 (JAK2) binding protein and initially named 
JBP1 (Pollack et al., 1999). JBP1 has since been established as the main type II PRMT, 
playing multiple roles in a wide range of cellular processes (Stopa et al., 2015). PRMT5 
is ubiquitously expressed and its catalytic domain is highly conserved across different 
23 
species. Importantly, its depletion during development results in early embryonic lethality 
(Tee et al., 2010). This loss of viability is attributed to the genomic instability accrued 
during global DNA demethylation, leaving blastocysts vulnerable to the transcriptional 
activation of harmful transposable elements (Kim et al., 2014). Another group 
demonstrated that conditional knockout of PRMT5 in neural stem/progenitor cells 
(NPCs) resulted in postnatal death in mice (Bezzi et al., 2013). Together, these findings 
suggest the indispensable role of PRMT5 in development, which is exerted by its 
methylation of a diverse array of histone and non-histone substrates. An illustrative list of 
known PRMT5 substrates is provided in Table 1.  
In addition to its association with developmental pathways, one of the primary 
functions of PRMT5 involves its extensive role in transcriptional regulation. This occurs 
most notably through methylation of histones or modulation of the activity of transcription 
factors. Moreover, several studies suggest that PRMT5 acts either as an activator or 
repressor of transcription depending on the substrate it modifies as well as the chromatin 
context. For instance, during the early stages of development, PRMT5 dimethylates 
H2AR3 (H2AR3me2s) which is critical for maintaining embryonic stem cell pluripotency 
through repression of differentiation genes (Gkountela et al., 2014; Vougiouklakis et al., 
2018). Others have shown that PRMT5 also associates with heterochromatin in erythroid 
progenitor cells, where it symmetrically dimethylates H4R3 (H4R3me2s) resulting in the 
recruitment of co-repressors to further potentiate gene repression (Zhao et al., 2009). 
Notably, symmetric dimethylation of H2A, H4R3 and H3R8 are considered general 
repressive marks and are usually targeted by PRMT5 in conjunction with chromatin-
remodeler complexes involved in gene silencing, namely, human SWItch/Sucrose Non-
Fermentable (hSWI/SNF) and SIN3 transcription regulator family member A/Histone 
deacetylase 2 (mSin3A/HDAC2) (Sharmistha Pal et al., 2004; S. Pal et al., 2003). On the 
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other hand, symmetric dimethylation of H3R2 (H3R2me2s) coincided with euchromatic 
regions which led to the recruitment of WDR5, a common component of co-activator 
complexes (Migliori et al., 2012). Importantly, H3R2me2s was associated with 
transcriptional activation needed for cell-cycle withdrawal and differentiation in human 
cells (Migliori et al., 2012). These findings indicate the indispensable histone-modifying 
role that PRMT5 plays in differentiation and embryonic developmental processes.  
PRMT5 has also been shown to regulate gene expression at the level of transcription 
elongation, translation and protein synthesis. For example, PRMT5-mediated 
methylation of a critical elongation factor, SPT5 was shown to regulate its interaction 
with RNA polymerase II, positively affecting its transcriptional elongation properties in 
response to viral and cellular factors (Kwak et al., 2003). Additionally, PRMT5 promoted 
the recruitment of eIF4e to the 5′ cap of MYC, HIF1α and Cyclin D mRNAs, indicative of 
its role in cellular and molecular processes such as survival, proliferation, transcription 
elongation, cell cycle regulation and cellular adaptation (Lim et al., 2014). Other less 
well-known but nevertheless essential roles for PRMT5 have been described, including 
regulation of ribosome biogenesis, metabolic gene reprogramming and Golgi apparatus 
integrity (L. Liu et al., 2016; Ren et al., 2010; Z. Zhou et al., 2010). 
Aside from histones, PRMT5 also dimethylates several key pleiotropic 
transcription factors (TFs), including p53, SREBP1, HOXA9, E2F-1, KLF4, PDCD4 and 
p65 (Shailesh et al., 2018). Through modulation of these TFs, PRMT5 can enact a wider 
repertoire of transcriptional changes related to many essential cellular processes 
including cell cycle regulation, proliferation, hematopoiesis, DNA damage response and 
metabolic reprogramming, among others. For example, in endothelial cells, PRMT5 
promotes transcription of pro-inflammatory and adhesion molecules by methylating 
HOXA9 which in turn promotes leukocyte adhesion and infiltration (Bandyopadhyay et 
al., 2012). Similarly, a separate study showed that TNF-α-induced and PRMT5-mediated 
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symmetric dimethylation of R30 and R35 of p65 in endothelial cells activated 
transcription of chemokines CXCL10 and CXCL11, which are also involved in the 
recruitment of inflammatory cells (Harris et al., 2014; Harris et al., 2016). These 
examples serve to enhance our understanding of the role of PRMT5-mediated 
methylation of TFs and provide important mechanistic insight into how certain gene 
networks such as those pertaining to inflammation can be modulated by arginine 
methylation. In addition to p65 and HOXA9, other TFs mentioned above cooperate with 
PRMT5 to drive pro-inflammatory and tumorigenic processes. We will elaborate upon a 
few of these in the subsequent section.  
PRMT5 also functions as a requisite factor in normal human hematopoiesis (F. 
Liu et al., 2015). Lui et al showed that deletion of PRMT5 in hematopoietic cells resulted 
in dysfunction of hematopoietic stem and progenitor cells which ultimately led bone 
marrow failure (F. Liu et al., 2015). Mechanistically, PRMT5-deficient hematopoietic 
stem cells exhibited severely attenuated cell surface expression of important cytokine 
receptors due to an impairment in the symmetric dimethylation of essential splicing 
proteins (Greenblatt et al., 2016). This brings us to another well-characterized biological 
function of PRMT5: regulation of the spliceosome machinery. In eukaryotic cells, splicing 
is a critical process for increasing the diversity of the proteome and improper functioning 
of splicesomal proteins contributes significantly to the susceptibility or severity of several 
diseases. PRMT5 maintains splicing fidelity by mediating methylation of SmB, SmD1 
and SmD3, facilitating their interaction with the survival motor neuron (SMN) complex 
and assembly into the pre-mRNA splicing core machinery (Bezzi et al., 2013; Meister et 
al., 2002). In the absence of PRMT5 however, defects in the splicing machinery 
produces unstable splice variants. One example is the generation of an abnormally 
spliced Mdm4 transcript in PRMT5-deficient hematopoietic cells. The mis-spliced Mdm4 
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product is unstable, leading to a reduction in Mdm4 protein levels and subsequent cell 
cycle arrest via aberrant activation of the p53 signaling pathway (Bezzi et al., 2013; 
Litzler et al., 2019). Clearly, PRMT5 functions as a master regulator of splicing in 
mammals which in turn serves to directly or indirectly affect many important downstream 
signaling pathways. The following section will provide a more detailed discourse on how 
these varied biological functions of PRMT5 are implicated in cancer. 
 
1.3.2B Contributions of PRMT5 to cancer 
Both the transcript and protein levels of PRMT5 are upregulated across several 
cancer types including but not limited to cancers of the bone marrow, breast, cervix, 
liver, pancreas, lung, ovaries, bladder, prostate and colon (Stopa et al., 2015). Moreover, 
overexpression of PRMT5 is strongly correlated to advanced tumor stages and poor 
patient outcome (Shailesh et al., 2018). Indeed, continuous efforts are underway to 
determine the clinical utility of PRMT5 overexpression as a possible diagnostic 
biomarker (Xiao et al., 2019). Although reports of this nature are rapidly expanding, the 
mechanisms underlying PRMT5’s suggested “oncogenic” role are yet to be fully 
elucidated. Thus far, PRMT5 has been implicated in the aberrant regulation of genes 
involved in cell proliferation, apoptosis, and DNA damage response (Xiao et al., 2019). 
Accumulating evidence suggests that among these genes are several tumor 
suppressors which are epigenetically inactivated upon PRMT5-mediated methylation of 
histones. For instance, PRMT5-catalyzed H3R8 and H4R3 symmetric dimethylation has 
been shown to repress expression of tumor suppressor genes ST7 and NM23 which 
coincided with increased transformation of NIH3T3 fibroblast cells (Karkhanis et al., 
2011; Sharmistha Pal et al., 2004). Likewise, in leukemia and lymphoma cells, 
upregulation of human SWI/SNF-associated PRMT5 was shown to be involved in the 
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transcriptional repression of retinoblastoma (RB) family of tumor suppressors including 
RB1, RBL1 and RBL2 (Wang et al., 2008). In the same study, depletion of PRMT5 
expression in B-cell chronic lymphocytic leukemia cells, WaC3CD5, abolished 
methylation of H3R8 and H4R3 which restored RB gene expression and hamper cancer 
cell proliferation (L. Wang et al., 2008). In another study, upregulation of PRMT5 in EBV-
driven transformed B-lymphocytes promoted recruitment of an HDAC3-repressive 
complex to the promoter of another tumor suppressor, Protein Tyrosine Phosphatase 
Receptor-type O (PTPROt) (Alinari et al., 2015). Expectedly, re-expression of PTPROt 
following PRMT5 inhibition led to mitigation of the malignant phenotype, suggesting 
PRMT5 inhibition could serve as a promising strategy for treating B-cell lymphomas. In a 
more recent study, overexpression of PRMT5 was detected in a large cohort of human 
gastric tumors where depletion of PRMT5 resulted in reduced cell growth and 
metastasis. Moreover, its upregulation contributed to increased recruitment of DNA 
methyltransferase 3A (DNMT3A) to the promoter region of the tumor suppressor gene, 
Iroquois homeobox 1 (IRX1), thus coupling histone and DNA methylation to promote 
gene silencing (X. Liu et al., 2018). Collectively, these results highlight the crucial role 
that PRMT5 overexpression plays in epigenetically repressing the transcription of key 
tumor suppressor genes and suggest a causal role of the associated elevated 
methylation of histones in promoting tumorigenesis. 
Aside from histone-related epigenetic modulation, evidence supporting PRMT5-
mediated alteration of tumor suppressor function is seen through its direct methylation 
of p53 in osteosarcoma cells. Dubbed the “guardian of the genome”, p53 is activated in 
response to DNA damage which results in apoptosis or cell-cycle arrest. Following 
DNA damage, PRMT5 was shown to methylate p53 within its oligomerization 
domain to modify its DNA binding activity and thus trigger altered target gene 
specificity (Jansson et al., 2008). For instance, ectopic PRMT5 enhanced the 
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expression of a p53-induced cell-cycle arrest gene program while reducing expression 
of signature genes related to apoptosis. Accordingly, PRMT5 depletion prompted 
apoptosis, suggesting that PRMT5 influences the outcome of the DNA damage 
response (Jansson et al., 2008). This differential outcome is significant in the context 
of anti-cancer therapy as p53-mediated apoptosis is considered a desirable outcome 
of DNA-damaging drugs. However, during p53-induced cell-cycle arrest, the cell 
attempts to repair DNA damage, perhaps with the assistance of genes such as 
Gadd45 that enhance its repair capacity (Pucci et al., 2000). Consequently, PRMT5-
catalyzed and p53-mediated induction of cell-cycle arrest not only favors survival and 
cell cycle arrest over apoptosis but may also interfere with and reduce the efficacy of 
drugs that target mitosis.  
In addition to its gene repressive functions and modulation of tumor repressors, 
PRMT5 overexpression is also intrinsically linked to enhanced gene activation which 
has been shown to promote cancer malignancy by orchestrating a cascade of 
downstream oncogenic signaling events. One pertinent example is that of the role of 
PRMT5 in promoting prostate cancer cell growth through epigenetic transcriptional 
activation of the androgen receptor (AR) (Deng et al., 2017). This receptor plays 
pivotal roles in prostate cancer and remains the major target of androgen blockade 
drugs used to treat castration-resistant prostate cancer (CRPC) (Rathkopf et al., 2013). 
However, quite often, prostate cancer cells adapt to these therapies and resistance 
emerges due to upregulation of AR expression, underscoring the need to identify 
mechanisms that lead to altered AR levels. In a recent study, PRMT5 and AR 
expression were concurrently elevated in prostate cancer tissues compared to their 
benign prostatic counterparts. Mechanistically, PRMT5 was recruited to the AR 
promoter through its interaction with Sp1, a critical transcriptional factor responsible for 
AR transcription. The net outcome of PRMT5 overexpression was upregulated AR 
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expression, facilitated by enriched symmetric dimethylation of H4R3 near the proximal 
AR promoter. Interestingly, this signifies a previously unreported activating role for the 
otherwise-known repressive H4R3me2s mark. Furthermore, knockdown or 
pharmacologic inhibition of PRMT5 suppressed the growth of AR-positive but not AR-
negative prostate cancer cells (Deng et al., 2017). These findings argue for the 
development of new and compelling personalized targeted therapies based on 
exploiting certain vulnerabilities conferred by PRMT5-mediated activation of genes 
such as AR.  
Further evidence in support of the gene activating role of PRMT5 in terms of its 
ability to enhance the proliferative capabilities of cancer cells comes from studies in CRC 
cells, which is the cancer of primary interest in the current dissertation work. In CRC 
cells, PRMT5-induced H3R8 and H4R3 symmetric methylation correlated with increased 
transcription of the Fibroblast-derived Growth Factor Receptor-3 (FGFR-3) and 
eukaryotic elongation Initiation Factor-4E (eIF4E) genes (B. Zhang et al., 2015). 
Conversely, inhibition of PRMT5 in response to AMI-1 treatment reduced the expression 
of these genes while inducing apoptosis in CRC cells and in a mouse CRC xenograft 
model (B. Zhang et al., 2015). In a separate study, overexpression and hyperactivity of 
PRMT5 in a subgroup of CRC cells was associated with poor clinical outcome via direct 
methylation and subsequent inhibition of E2F-mediated growth control, thereby 
contributing to uncontrolled cell proliferation (Cho et al., 2012). Intriguingly, a recent 
study by Zheng et al (2017) demonstrated a novel functional link between PRMT5 and 
ulcerative colitis (UC), a major risk factor for CRC initiation. Depletion or 
pharmacological inhibition of PRMT5 enhanced the levels and function of regulatory T 
cells (Tregs) while attenuating UC in a mouse model of dextran sulfate sodium (DSS)-
induced colitis. Furthermore, blockade of PRMT5 in Tregs also led to a decreased 
transcription of pro-inflammatory cytokines TNFα, IL6, and IL-13, implicating a role for 
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PRMT5-mediated gene regulation in the modulation of inflammatory responses (Y. 
Zheng et al., 2017). Remarkably, our lab previously demonstrated a role for PRMT5 in 
pro-inflammatory cytokine-activated transduction pathways. We found that NF-κB is 
dimethylated on R30 in response to IL-1β-stimulation of PRMT5, which was found to 
profoundly regulate NF-κB activation of more than 75% of its target genes. These genes 
include TNF-α, Interleukin 8 (IL8), and mitogen-activated protein kinase kinase kinase 8 
(MAP3K8), all implicated as being essential in inflammation and cancer (Wei et al., 
2013). Similarly, later studies from another group showed that PRMT5-mediated p65 
methylation was essential for NF-κB-dependent induction of CXCL10 and CXCL11, 
chemokines critical for the recruitment of immune cells to inflammatory sites (Harris et 
al., 2014; Harris et al., 2016). Thus, targeting PRMT5 presents a promising therapeutic 
approach to moderating chronic inflammatory pathologies, including cancer.   
Collectively, the spectrum of PRMT5 target proteins (Table 1) provides strong 
evidence for its complicated and sophisticated involvement in a wide array of signaling 
pathways which also implies that PRMT5 might function in the context of multiple 
oncogenic drivers (Figure 7). In the future, it will be interesting to explore the possible 
mutual interplay between these signaling pathways and varied substrates of PRMT5.  
Importantly, cataloging these nodes of crosstalk will provide crucial insight for the 
rational development of anti-cancer combination therapies aimed at targeting multiple 








Figure 5: Classification of PRMT family members based on methylation patterns 
(Bedford et al., 2009). Three distinct types of methylated arginine residues exist in 
mammalian cells: monomethylarginine (MMA), asymmetric dimethylargine (ADMA) and 
symmetric dimethylarginine (SDMA). All PRMT family members catalyze the formation of 
MMA as an intermediate by adding one methyl group on of the terminal (ω) guanidine 
nitrogen atoms. ADMA marks are catalyzed by Type I enzymes of which CARM1 is the 
most prominent. ADMA marks are generated by the addition of two methyl groups on the 
same terminal (ω) guanidine nitrogen atom whereas SDMA marks are formed by the 
addition of a methyl group on each of the two terminal nitrogens. This is catalyzed by 
Type II PRMTs of which PRMT5 is the most prominent. PRMT7 is the only type III 
enzyme, which mainly generates MMA. The main enzymes for each type of methylation 







Figure 6: Domain architecture of human PRMTs (Schapira et al., 2014). There are 
currently nine members of the mammalian PRMT family, which harbor highly conserved 
domains including the catalytic domain (Rossman fold), α-helix and β-barrel. The 
number of residues is indicated at the C terminus of the PRMTs and additional signature 
domains are indicated. SH3: SRC Homology 3 Domain; ZnF: Zinc finger; PH: Pleckstrin 
















Figure 7: Schematic model of various PRMT5-regulated signaling molecules, pathways 
and cellular processes (Karkhanis et al., 2011). PRMT5 regulates various cellular 
processes via different mechanisms including modification of key regulatory factors such 
as transcription factors (e.g., p53, KLF4, NF-κB), receptors (e.g., EGFR, FGFR3), Golgi 
proteins (GM130) and ribosomal proteins (RPS10). Together, these PRMT5-mediated 
alterations profoundly affect signaling pathways related to apoptosis, proliferation, pro-













1.3.3 Regulation of PRMT5 by interacting partners 
PRMT5 can be regulated at multiple levels (Figure 8) and is principally active as 
part of a larger multimeric complex which associates with a broad range of interacting 
partners (Antonysamy, 2017). By and large, these interactions regulate its activity and/or 
substrate specificity.  MEP50 is considered to be a major cofactor of PRMT5 and 
together, they form a catalytically active hetero-octameric complex in vitro which also 
serves to define its substrate specificity as well as its distributive catalytic mode of action 
(Antonysamy, 2017). However, whether MEP50 is obligatory for PRMT5 function in vivo 
remains uncertain. Nevertheless, the MEP50-PRMT5 interaction appears to primarily 
promote methylation of histones whereas other cofactors such as Blimp1, Menin/Men1 
and members of the hSWI/SNF chromatin remodeling complex may elicit methylation 
specificity towards other substrates including nucleosomes (Stopa et al., 2015). Another 
cofactor, cooperator of PRMT5 (COPR5), was found to predominantly interact with 
PRMT5 in the nucleus and appeared to be partly responsible for PRMT5’s transcriptional 
repressor activities (Lacroix et al., 2008). Interestingly, when complexed with COPR5, 
PRMT5 also preferentially methylated H4R3 over H3R8, introducing yet another layer of 
complexity that involves more subtle distinguishing between histone substrates ( 
Karkhanis et al., 2011).  Likewise, other proteins of the PRMT5 interactome have been 
shown to trigger preferential recruitment of PRMT5 for the repression of gene 
expression. Association of bromodomain protein 7 (BRD7) with the PRMT5-containing 
hSWI/SNF chromatin remodeling complex correlated with PRMT5 recruitment to, and 
subsequent hypermethylation of H3R8 and H4R3 at the promoters of ST7 and RBL2 
(Tae et al., 2011). 
Interestingly, the interaction of one binding partner of PRMT5 can also preclude 
its complex with another, which may further dictate substrate selectivity. The mutually 
exclusive interaction of PRMT5 with the adaptor proteins, plCln and RioK1 is a chief 
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example. Association of RioK1 with PRMT5 targets PRMT5-mediated methylation of 
nucleolin, a phosphoprotein involved in the synthesis and maturation of ribosomes. On 
the other hand, pICln precludes the binding of PRMT5 to Riok1 and instead, directs 
recruitment of Sm proteins for their symmetric dimethylation by PRMT5 to form small 
nuclear ribonucleoproteins (Guderian et al., 2011). Furthermore, PRMT5-pICln was also 
shown to inhibit the methylation of histones. In total, these findings provide key 
mechanistic insight into how protein-protein interactions (PPIs) orchestrate the 
distinction between different substrate proteins, which may be useful for the rational 
design of PRMT5-specific inhibitors that perturb these PPIs. 
 
1.3.4 Regulation of PRMT5 by existing substrate modifications 
The existence of other types of PTMs can also alter the activity of PRMT5 
towards a given substrate. For instance, pre-existing acetyl marks on H4K5 and H4K16 
were shown to facilitate deposition of PRMT5-mediated H4R3me2s marks. However, 
whether the reverse is true where H4R3me2s promotes these acetylation events 
remains to be established (Feng et al., 2011). Conversely, phosphorylation of H2AS1 
and H4S1 had an inhibitory effect on PRMT5 activity (Ho et al., 2013). Stopa et al 
hypothesized that the latter may be due to steric hindrance conferred by the bulkier 
phosphorylation moiety (Stopa et al., 2015). Together, these reports not only highlight 
another mechanism by which arginine methylation is regulated, via induction of crosstalk 
between different PTMs, but signifies the complex interplay between PRMTs and other 
classes of enzymes including histone acetyltransferases (HATs) and kinases.  
 
1.3.5 Regulation of the subcellular localization of PRMT5 
Although predominantly cytoplasmic, PRMT5 has been shown to localize to the 
nucleus, Golgi apparatus and cell membrane. Intriguingly, the subcellular localization of 
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PRMT5 appears to be temporally and dynamically governed by factors such as 
developmental stage, cell-type, and disease state.  For example, during early embryonic 
stages PRMT5 interacts with Blimp1 and is localized to the nucleus in mouse primordial 
germ cells (Ancelin et al., 2006). This is linked to high levels of symmetric dimethylation 
of H2A and H4R3. However, by E11.5 Blimp1 is downregulated and PRMT5 persists in 
the cytoplasm, thus decreasing nuclear H2A/H4R3 methylation levels. This shuttling of 
PRMT5 between the nucleus and the cytoplasm ensures temporal silencing of 
transposons and maintenance of genomic integrity during extensive, global DNA 
demethylation (Ancelin et al., 2006). Conversely, in human zygotes and early embryos, 
PRMT5 is cytoplasmic, but thereafter becomes nuclear up until the early E3.5 blastocyst 
stage which coincides with enriched H2A/H4R3me2s levels. It then becomes mostly 
cytoplasmic once again (Kim et al., 2014). In embryonic stem cells, PRMT5 is also co-
upregulated with STAT3 in the cytoplasm to maintain pluripotency via repression of 
differentiation genes (Tee et al., 2010).   
Compartmentalization of PRMT5 not only varies across different cell types and 
developmental stages but is also implicated as holding prognostic value in various 
cancers.  In fetal germ cells, PRMT5 is cytoplasmic; however, in Leydig and adult 
testicular cells, it is nuclear. This pattern is reversed in Leydig tumor cells, in which 
PRMT5 shows an increased cytoplasmic localization (Eckert et al., 2008). Moreover, 
cytoplasmic localization of PRMT5 was shown to correlate with poor prognosis in high-
grade, poorly differentiated lung adenocarcinomas, whereas a predominantly nuclear 
PRMT5 was identified in low-grade tumors (Ibrahim et al., 2014; Shilo et al., 2013).  
In prostate cancer cells, PRMT5 was found to function in opposite ways in the cytoplasm 
and nucleus. While nuclear PRMT5 was observed in benign prostate epithelium, it 
primarily localized to the cytoplasm in neoplastic and malignant prostate cancer tissues 
(Gu, Li, et al., 2012). Correspondingly, cytoplasmic PRMT5 promoted cell proliferation in 
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a methyltransferase-dependent manner whereas nuclear localization of PRMT5 had a 
growth-inhibitory effect (Gu, Li, et al., 2012). Additional studies showed that compared to 
their benign counterparts, melanoma tissues exhibited higher cytoplasmic PRMT5 
(Nicholas et al., 2013). By contrast, nuclear PRMT5 was associated with poor overall 
survival in oropharyngeal squamous cell carcinomas (Kumar et al., 2017). Overall, the 
compartment-related functional dichotomy described above appears to be linked to the 
association of nuclear or cytoplasmic PRMT5 with, and subsequent silencing and/or 
activation of various molecular targets, albeit the exact mechanisms are yet to be 
determined. 
PRMT5 was shown to also localize to the Golgi and to be in proximity of the cell 
membrane. In the Golgi, it associates with and methylates GM130, a Golgi matrix protein 
required for the transitioning of ER vesicular to Golgi-specific cisternal membranes. 
Depletion of PRMT5 led to impaired Golgi ribbon formation indicating the critical role of 
PRMT5 in maintaining the overall integrity of this organelle (Z. Zhou et al., 2010). At the 
cell membrane, PRMT5 has been shown to methylate R1175 on EGFR, dampening the 
effect of EGF-stimulated ERK activation (Hsu et al., 2011).  
Taken together, these findings clearly suggest that symmetric arginine 
methylation is a tightly controlled PTM as evidenced by a strong correlation between 
PRMT5 localization and the distinct functional outcomes observed.  Mechanistically, the 
cytoplasmic localization may be explained by deletion analyses which revealed that 
PRMT5 harbors three nuclear exclusion signals (NESs) (Gu, Gao, et al., 2012). 
However, since other localization motifs (e.g., NLS) are yet to be identified within the 
PRMT5 protein, future studies to determine specific signaling cues or binding partners 




1.3.6 Transcriptional and post-transcriptional regulation of PRMT5 
It is widely appreciated that the overexpression of PRMT5 contributes to the 
development and progression of several human cancers. However, the mechanisms 
underlying transcriptional regulation of PRMT5 expression remain elusive. Recent 
studies identified nuclear transcription factor Y A (NF-YA) as a critical transcription factor 
that binds CCAAT boxes within the promoter region of PRMT5. Knockdown of NF-YA 
resulted in loss of PRMT5 expression and consequent growth defects of prostate cancer 
cells in a PKC/c-Fos-dependent manner (H.-T. Zhang et al., 2014). Another pertinent 
study using a mouse lymphomagenesis model, showed that oncogenic MYC could 
directly upregulate PRMT5 whereas in AML cells, the polymerase-associated factor 
complex (PAFc) indirectly amplified its expression (Koh et al., 2015; Serio et al., 2018). 
Interestingly, a more recent study provided evidence for the possible epigenetic 
regulation of PRMT5 expression. Depletion of the HAT, N-alpha-acetyltransferase 40 
(NAA40) in CRC cells was shown to significantly reduce and enhance the enrichment of 
activating N-acH4 and repressive H3K27me3 marks, respectively, at the promoter of 
PRMT5. This corresponded to decreased levels of H4R3me2 through repression of 
PRMT5 expression. The net outcome was altered expression of key oncogenes and 
tumor suppressor genes regulated by PRMT5 which ultimately led to inhibition of CRC 
cell growth (Demetriadou et al., 2019). Altogether, these studies reveal another complex 
node in the multi-layered regulation of PRMT5. However, the paucity of reports in this 
area suggests an overall lag in uncovering the most critical transcription factors that 
drive PRMT5 expression, yet this knowledge is essential to effectively exploiting these 
factors for novel anti-cancer therapies. 
Lately, several correlative studies suggest that PRMT5 is also regulated at the 
post-transcriptional level by the 3I-UTR targeted action of several miRNAs including miR-
92b and miR-96. In a panel of mantle cell lymphoma (MCL) and lymphoid cancer cell 
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lines, decreased miR-92b and miR-96 expression was shown to augment PRMT5 
translation which was accompanied by increased H3R8/H4R3 methylation and 
subsequent repression of ST7. Furthermore, re-expression of miR-92b and miR-96 
miRNAs resulted in a corresponding decrease in PRMT5 protein levels (Sharmistha Pal 
et al., 2007). Similar effects were observed in transformed B cell chronic lymphocytic 
leukemia (B-CLL) cells. Intriguingly, recent studies also suggest that PRMT5 participates 
in several regulatory feedback circuits with miRNAs in which PRMT5 might promote its 
own expression through epigenetic silencing of specific miRNA gene programs, 
suggesting a mutual interplay and coordinated regulation between PRMT5 and miRNAs 
for the maintenance of cancerous phenotypes (Vrajesh Karkhanis et al., 2014). 
Arguably, whether targeting these upstream determinants of PRMT5 expression will 
likely lead to a general clinical advantage for patients, remains to be elucidated. Hence, 
future translational studies are needed to identify patient populations that could benefit 
from multipronged targeting of PRMT5, involving direct inhibition PRMT5 activity as well 
blocking upstream factors that contribute to its aberrant expression.  
 
1.3.7 Regulation of PRMT5 by posttranslational modifications 
Like other methyltransferases, PRMT5’s activity is also fine-tuned by PTMs such 
as phosphorylation, methylation and ubiquitination. Tyrosine phosphorylation constitutes 
one of the earliest evidences of posttranslational regulation of PRMT5. Phosphorylation 
of Tyr304 and Tyr307 by oncogenic JAK2V617F mutant was shown to downregulate the 
methyltransferase activity of PRMT5 via disruption of the PRMT5-MEP50 interaction to 
promote myeloproliferation (F. Liu et al., 2011). In another study, phosphorylation of a 
threonine residue, T634, functioned to target PRMT5 to the plasma membrane via 
modulation of a PRMT5 interaction switch involving PDZ and 14-3-3 (Espejo et al., 
2017). In the current study, we reveal a novel regulatory role for serine phosphorylation 
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of PRMT5 within the TIM-Barrel domain of PRMT5 in CRC cells. In the subsequent 
sections, we demonstrate that IL-1β-inducible phosphorylation of S15 positively 
regulates its methyltransferase activity and complexing with the p65 subunit of NF-ĸB 
which may undergird one aspect of its tumor-promoting role in CRC cells. Interestingly, 
another recent study by Lattouf et al also identified threonine phosphorylation sites 
within the same TIM-Barrel motif of PRMT5 in breast cancer cells. Point mutations of 
T132, T139 and T144 residues on PRMT5 resulted in its dissociation from its binding 
partners MEP50, pICln and RioK1, leading to overall lower methyltransferase activity 
(Lattouf et al., 2019). These latter studies argue for a potentially new regulatory 
mechanism involving phosphorylation of residues within the TIM-Barrel, a domain unique 
to PRMT5. Furthermore, identification of these PTMs across different cancer tissues 
could potentially have clinical implications in identifying specific subsets of patients 
where phosphorylation of PRMT5 may mediate its tumor-associated roles. 
Apart from phosphorylation, the role of other PTMs in regulating PRMT5 has 
been described. For instance, Nie et al identified methylation of PRMT5 as a positive 
regulator of its catalytic activity. CARM1 was recently shown to directly interact with, and 
asymmetrically dimethylate PRMT5 on R505, to promote its oligomerization and thus 
enhance its methyltransferase activity (Nie et al., 2018). On the other hand, 
polyubiquitination of PRMT5 by the ligase CHIP was found to be essential to the 
negative regulation of PRMT5 expression via K48-linked ubiquitin-dependent 
proteasomal degradation in pancreatic cancer cells (H. T. Zhang et al., 2016). Taken 
together, these findings support a complex model of the regulation of PRMT5 by PTMs 
that define its methyltransferase activity, protein-protein interactions and stability. To our 
knowledge, the work outlined in this thesis is the first report of a cytokine-induced 
modification on PRMT5. This is a significant observation since cytokines play critical 
roles in modulating tumor-related processes. Indeed, further understanding of the 
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extracellular clues that underlie the other afore-mentioned PTMs may serve as the basis 



















Figure 8: Multi-level regulation of PRMT5. 1) Cofactor (e.g., MEP50) and adaptor 
proteins (e.g., RioK1) bridge the interaction between PRMT5 and specific substrates, 
targeting them for methylation. 2) PRMT5 can be regulated by shuttling between the 
nucleus and the cytoplasm, thus positioning it to interact with and methylate different 
substrate proteins. 3) Distinct PTMs such as phosphorylation, methylation and 
ubiquitination have been shown to modulate the activity of PRMT5.4) The pre-existence 
of other PTMs on the substrate can facilitate (e.g., acetylation) or prevent (e.g., 
phosphorylation) adjacent arginine methylation. 5) PRMT5 can be targeted for mRNA 
cleavage and translational repression through the action of miRNAs. Finally, 6) The 
transcriptional levels of PRMT5 can also be modulated upstream by transcription factor-































































1.4 Summary and Hypotheses 
A plethora of findings suggest that the p65 subunit of NF-ĸB undergoes a variety 
of PTMs and that these events are critical to modulating the transcriptional output NF-ĸB 
(Huang et al., 2010). Importantly, recent findings from our lab represent the first report of 
PRMT5-mediated arginine methylation of p65 at R30 as being another critical 
modification involved in regulating a subset of IL-1β-inducible NF-ĸB-dependent genes 
(Wei et al., 2013). Moreover, in the same study, supporting evidence from illumina array 
data suggests that majority of the genes (~85%) downregulated by the R30A mutant 
were also downregulated by depletion of PRMT5. The results from this cross-
comparison are significant since PRMT5 is highly overexpressed across many cancer 
types in which constitutive activation of NF-ĸB is also implicated, including CRC. As 
such, we hypothesized that high levels of this enzyme may promote CRC malignancy at 
least in part, by facilitating aberrant NF-κB-induced gene expression. Indeed, findings 
from the current and previous work reveal that overexpression of PRMT5 significantly 
augments NF-ĸB activation and target gene transcription concurrent with promoting the 
migration, proliferation and anchorage-independent growth of CRC cells. However, the 
precise mechanisms governing this PRMT5/NF-B regulatory axis are unknown. In this 
regard, the work described here focuses on the phospho-mediated regulation of this axis 
based on our discovery of a novel S15 phosphorylation site on PRMT5.  We propose 
that phosphorylation of PRMT5 at S15 is critical to its activation of NF-ĸB and partially 
contributes to the tumor-associated roles of PRMT5 in CRC. In summary, the findings 
from this study highlight a new regulatory mechanism of PRMT5 via IL-1β-inducible 





CHAPTER 2: METHODS 
2.1 In Vitro experiments 
2.1.1 Liquid chromatography-tandem mass spectrometric analysis  
Coomassie-stained SDS-PAGE gel band containing Flag-PRMT5 protein was 
subjected to in-gel tryptic digestion. Flag-PRMT5 gel pieces were subjected to 
destaining and reduction of cysteine residues using 50% acetonitrile in 100 mM 
ammonium bicarbonate and 100% acetonitrile followed by treatment, followed by 20 mM 
DTT at room temperature for 60 min. Alkylation with 55 mM iodoacetamide for 30 min 
was performed in the dark. The solution was removed and the gel pieces were washed 
with 100 mM ammonium bicarbonate and dehydrated in acetonitrile. Gel pieces were 
then dried in a SpeedVac centrifuge, and proteolytically digested by rehydration 
overnight at 37 °C in 50 mM ammonium bicarbonate containing sequencing grade 
modified trypsin (Promega, WI).  Extracted peptides were treated with 50% acetonitrile in 
5% formic acid, dried and reconstituted in 0.1% formic acid for mass spectrometry 
analysis. Analysis of proteolytic digests was performed by using an LTQ Orbitrap XL 
linear ion-trap mass spectrometer (Thermo Fisher Scientific), coupled with an Ultimate 
3000 HPLC system (Dionex). The digests were injected onto a reverse-phase C18 
column (0.075 × 150 mm, Dionex) equilibrated with 0.1% formic acid/4% acetonitrile 
(vol/vol). A linear gradient of acetonitrile from 4 to 40% in water in the presence of 0.1% 
formic acid over a period of 45 min was used at a flow rate of 300nL/min. The spectra 
were acquired by data dependent methods, consisting of a full scan (m/z 400–2,000) 
and then tandems on the five most abundant precursor ions. The previously selected 
precursor ions were scanned once during 30 s and then were excluded for 30 s. The 
obtained data were analyzed by Mascot software (Matrix Science) against customized 
PRMT5 protein database with the setting of 10 ppm for precursor ions and 0.8 Da for 
product ions. Carbamidomethylation of cysteine was set as fixed modification, while 
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oxidation of methionine, phosphorylation of serine, threonine, and tyrosine were set as 
variable modifications. The tandem mass spectra of candidate-modified peptides were 
further interpreted manually. 
 
2.1.2 Cell lines & materials 
The 293IL1R (denoted as HEK293) cell line was previously described by Lu et al, 
2010 (Lu et al., 2010). HEK293 cells were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) (GE Healthcare), supplemented with 1% of penicillin/streptomycin and 
5% fetal bovine serum (FBS). CRC cell lines HT29, DLD1 and HCT116 were procured 
from American Type Culture Collection (ATCC) (Manassas, VA) and were cultivated in 
RPMI (Roswell Park Memorial Institute, Buffalo, NY) 1640 medium supplemented with 
100 units/ml penicillin, 100 g/ml streptomycin, and 5% fetal bovine serum (FBS). Cell 
lines were authenticated using 9 Marker STR Profile by IDEXX Bioresearch. 
 
2.1.3 Generation of stable PRMT5-overexpressing cell lines 
Flag-tagged WT-PRMT5 cDNA construct was amplified from total mRNA derived 
from HEK293 cells and cloned into the pLVX-IRES-puro vector (Lu et al., 2010). The 
Flag-S15A-PRMT5 and E444D mutants of PRMT5 was generated using the 
QuikChange II XL Site-Directed Mutagenesis Kit from Agilent Technologies. Primers 
were designed using the Agilent Technologies QuikChange Primer Design online 
software and are outlined in Appendix C. Constructs were transfected into HEK293C6 
and CRC cell lines as essentially described by Lu et al using Lipofectamine and PLUS 
reagents (Life Technologies/Invitrogen, Carlsbad, CA) (Lu et al., 2010). For the 
generation of stable PKCɩ knockdown cell lines, a pool of 5 shRNAs constructs against 
PKCɩ were employed (Sigma-Aldrich). The respective lentiviral plasmids containing 
empty vector, Flag-WT-PRMT5, Flag-S15A-PRMT5  or shRNA against PKCɩ were 
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transected into a high efficiency 293T packaging cell line to produce high-titer viral preps 
that were used to infect HEK293 or a panel of CRC cells. Upon 48h of infection, cells 
were selected under 1μg/mL of puromycin and verified for the expression of various 
proteins by western blot analyses.  
 
2.1.4 Western blotting and antibodies  
Cells were cultured to about 90-95% confluence. Whole cell samples were 
collected in 1X phosphate buffered saline (PBS), centrifuged at 5,500 rpm for 5 min and 
lysed using Radio Immunoprecipitation Assay buffer (RIPA buffer: 150 mM NaCl, 0.1% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM 
Tris-HCl pH 8.0, 1 mM PMSF and protease inhibitors). The protein concentration of each 
sample was tested using the Protein Assay Reagent (Biorad) assay and absorbance 
values measured using a Genesys 10S Vis spectrophotometer (Thermo Fisher 
Scientific).  Equal protein concentrations in 2X SDS sample loading buffer [100mM Tris-
Cl, pH 6.8, 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) glycerol, 200mM β-
mercaptoethanol] were loaded and separated by SDS/PAGE gels followed by further 
assessment by western blotting. Different antibodies were used to detect the target 
proteins of interest, obtained from the following commercial sources: anti-PRMT5 
(Abcam, ab109451), anti-Flag (Sigma-Aldrich, F1804), and anti-p65 (Santa Cruz 
Biotechnology, sc-109); anti-PKCɩ (Proteintech, 66493-1-Ig). For cell fractionation 
experiments, cytoplasmic and nuclear fractions were subject to SDS-PAGE and probed 
with anti-LaminB1 (Proteintech, 12987-1-AP); anti-α-tubulin (Cell Signal, 2144S). The 
enhanced chemiluminescence (ECL) detection method (PerkinElmer) was used to 




2.1.5 NF-ĸB luciferase assay 
NF-κB luciferase assays were conducted by infecting respective stable cell lines 
with a lentivirus originally generated in 293T cells using the κB-luciferase construct 
p5XIP10 κB and Lipofectamine™ LTX Reagent and PLUS Reagents (Thermo Fisher 
Scientific). Luciferase activity was assayed 48 h later using the Luciferase Assay System 
with Reporter Lysis Buffer kit (Promega, Fitchburg, WI). The κB-luciferase plasmid 
p5XIP10 κB contains five tandem copies of the NF-κB DNA binding site derived from the 
IP10 gene (an established target gene of NF-κB) upstream of a luciferase reporter gene. 
Luciferase activity was quantified using a Synergy H1 Multi-Mode Reader (BioTek 
Instruments Inc., Winooski, VT). All readings were normalized to total protein amount per 
condition.  
 
2.1.6 Illumina microarray & quantitative PCR 
Microarray and qPCR experiments were carried out as essentially described 
(Wei et al., 2013). Briefly, control or HEK293 cells with WT-PRMT5 or S15A-PRMT5 
overexpression were cultured to ~90% confluence and total RNA was isolated using 
Trizol reagent (Invitrogen, Carlsbad, CA). Total isolated RNA was used to prepare cDNA 
using the SuperScript III First-Strand Synthesis PCR System (Invitrogen, Carlsbad, CA). 
cDNA was labeled with biotin-UTP using the Illumina Total Prep RNA amplification kit 
(Ambion/Applied Biosystems, Foster City, CA), hybridized to Illumina Human Ref-v3 v1 
Expression Bead Chips and then scanned in a Bead Array reader using standard 
Illumina protocols (Illumina, San Diego, CA). Illumina’s Bead Studio software was used 
for data analysis. qPCR was carried out using FastStart Universal SYBR Green Master 
ROX (Roche, Basel, Switzerland). Primers were designed by the Primer Express 3.0 
software. Primer information is listed in Appendix B. 
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2.1.7 AlphaLISA-based H4R3me2 detection assay 
Flag-WT-PRMT5 or S15A-PRMT5 and E444D mutant enzymes was purified from 
293 cells using anti-Flag-M2 beads (Sigma-Aldrich, St. Louis, MO) as described in co-
immunoprecipitation methods above. The enzyme prep was diluted in assay buffer 
(30mM Tris, pH 8.0, 1mM DTT, 0.01% BSA, 0.01% Tween-20) prior to use. SAM (New 
England Biolabs, Ipswich, MA) and unmethylated peptide of histone H4R3 (Anaspec, 
Fremont, CA) were used as the methyl group donor and PRMT5 enzyme substrate, 
respectively. The 23-amino acid sequence of H4R3 peptide was as follows: 
SGRGKGGKGLGKGGAKRHRKVLRGG-K(biotin)-NH2, with the third arginine site 
available for symmetric dimethylation per the assay protocol. 
Acceptor beads diluted in 1X Epigenetics buffer (PerkinElmer, Waltham, MA) 
were added at a final concentration of 20 μg/ml to the reaction mixture and the plate was 
incubated at R.T. for 1 hr. Streptavidin-tagged donor beads diluted in 1X Epigenetics 
buffer (PerkinElmer, Waltham, MA) were then added at a final concentration of 20 μg/ml 
and the plate was further incubated at R.T. for 30 min. All reactions were performed in 
triplicate and repeated three independent times. The plates were read using an 
EnVision® Reader. 
 
2.1.8 Co-immunoprecipitation assay 
Cells stably expressing Flag-PRMT5 proteins were cultured to 95% confluency 
then lysed in co-immunoprecipitation buffer (1% Triton X-100 (v/v), 50mM Tris-HCl, pH 
7.4), 150mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 20 µM aprotinin, 1 mM 
phenylmethanesulfonyl fluoride, and 1 mM pepstatin A) and vortexed every 4 times 
every 5 mins on ice.  The cells were centrifuged at 3,400 rpm for 30 min, and the whole 
cell lysate (WCL) was transferred to the prewashed anti-Flag-M2 beads (Sigma-Aldrich, 
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St. Louis, MO) suspended in 1X cold PBS. The WCL/bead mixture was rotated at 4°C, 
overnight.  Beads containing the Flag/protein complexes were then washed 4 times 
using 1X wash buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 0.5% Triton X-
100) followed by rotation with Flag peptide dissolved in TBS (in 10mM Tris HCl, 150 mM 
NaCl, pH7.4) for 1 h at 4°C to competitively elute Flag-tagged proteins from the anti-
FLAG M2 beads.  Eluates were then subjected to SDS/PAGE.  
 
2.1.9 Ingenuity Pathway Analyses 
Groups of genes regulated by S15A-PRMT5 were analyzed by the Ingenuity 
Pathway Analyses (IPA) software. The setting and filter were as follows: reference set: 
Ingenuity Knowledge Base (Genes _ Endogenous Chemicals); Relationship to include: 
Direct and Indirect; Includes Endogenous Chemicals; Filter Summary: Consider only 
molecules where species _ Human OR Rat OR Mouse. The p values for the enrichment 
test were calculated using Fisher’s exact test, right-tailed. Log10 (p) was visualized to 
the left of the p value. p<0.05 was considered to be statistically significant. 
 
2.1.10 Cell growth assay 
For cell growth assays, CRC cells overexpressing Flag-PRMT5 constructs were 
seeded in triplicate at 2 X104 cells/well in a 6-well plate. Cells were counted at days 3, 5, 
7 and 9 post-seeding using a cell hemocytometer counting chamber. 
 
2.1.11 Boyden chamber cell migration assay 
Migration assays were conducted using Boyden chambers. Briefly, a Boyden 
chamber consists of 8μm pore size cell culture inserts in a 24 well plate. Each insert was 
coated with gelatin on the side facing the lower chamber. 2X105 cells were seeded in the 
top of the insert (upper chamber) in serum-free media while serum-rich media (10% 
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serum) was supplied in the well below as a chemoattractant. After 48h, migrated cells 
were fixed with 4% formaldehyde and stained with crystal violet. Stained cells were 
visualized with a light microscope at 20X magnification and quantified. Images were 
captured using a Canon EOS Rebel T3i Digital SLR camera. 
 
2.1.12 Anchorage-independent growth assay 
For anchorage-independent growth assays, type VII agarose (Sigma-Aldrich, St. 
Louis, MO) was used to prepare 2.4% and 1.2% bottom and top agar layers, 
respectively. 2 X 105 cells were resuspended in the top layer and plated onto the bottom 
layer. Cells were then cultured for 12-14 days at 37°C and 5% CO2.  Images of colonies 
were captured using a Canon EOS Rebel T3i Digital SLR camera and colony size and 
number were quantified using the ImageJ software (http://imagej.nih.gov/ij/). 
 
2.1.13 Human cytokine array 
Human Cytokine ELISA Array was purchased from Signosis and carried out 
according to the manufacturer’s protocol (Signosis, San Francisco, CA). Briefly, 72hr 
conditioned media collected from HT29 control, HT29-WT-PRMT5, or S15A-PRMT5 
stable cell lines was added to specific cytokine capture antibodies pre-coated wells for 2 
h at R.T. After incubation, the wells were washed to remove unbound-labeled antibodies. 
The plate was further detected with HRP luminescent substrate. The level of expression 
for each specific cytokine was directly proportional to the emitted luminescence. 
 
2.1.14 Chromatin immunoprecipitation-PCR assay 
Cells were left untreated or stimulated with 10 ng/mL IL-1β for 1h and 4hrs and 
cross-linked with 1% formaldehyde for 10 min at room temperature. The cross-linking 
was stopped by adding glycine and cells were then washed with cold PBS, scraped, and 
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pelleted by centrifugation at 2000rpm. Cells were lysed in Farnham Lysis buffer [5mM 
PIPES pH 8.0/85 mM KCl/0.5% Tween 20] supplemented with protease inhibitors 
followed by chromatin shearing to yield fragments of 200–1,000 bp using a sonifier 
(Fisher Scientific, Hampton, NH) equipped with a microtip (40 secs on/50secs off, 4 mins 
at 40% power output). Sonicated lysates were centrifuged, and the resulting supernatant 
was diluted 5-fold with ChIP dilution buffer containing 16.7 mM Tris⋅HCl pH 8.1, 167 mM 
NaCl, 0.01% SDS, 1.1% (vol/vol) Triton X-100, and 1.2 mM EDTA. Diluted lysates were 
precleared for 1 h with protein A/G agarose. Immunoprecipitations were performed using 
ChIP-grade anti-RelA (Abcam, ab7970, Cambridge, United Kingdom) antibody at 4 °C 
overnight. Immune complexes were collected with protein A/G agarose, washed  with 
low-salt wash buffer [20 mM Tris⋅HCl pH 8.1, 150 mM NaCl, 0.1% SDS, 1% (vol/vol) 
Triton X-100, and 2 mM EDTA], high-salt wash buffer [20 mM Tris⋅HCl pH 8.1, 500 mM 
NaCl, 0.1% SDS, 1% (vol/vol) Triton X-100, and 2 mM EDTA],  LiCl wash buffer [10 mM 
Tris⋅HCl pH 8.1, 250 mM LiCl, 1% (wt/vol) sodium deoxycholate, 1% (vol/vol) IGEPAL-
CA630, and 1 mM EDTA], and TE buffer (10 mM Tris⋅HCl pH 8.0 and 1 mM EDTA). 
Protein-DNA complexes were eluted from antibodies with elution buffer containing 1% 
SDS and 0.1 M NaHCO3, incubated in the presence of 192 mM NaCl for 4 h at 65 °C, 
and digested with proteinase K for 1 h at 45 °C. DNA was recovered using the Qiagen 
quick DNA purification kit and IL8 gene-specific ChIP primers (Qiagen, Hilden, Germany) 
were used in the PCR analyses. Primer sequences are listed in Appendix B.  
 
2.1.15 Cell fractionation assay 
Fractionation experiments were conducted according to the manufacturer's 
instructions for the nuclear extract kit (Active Motif, Carlsbad, CA). Briefly, cells were 
grown to about 80% confluence, washed with ice-cold PBS/Phosphatase inhibitors, 
collected and pelleted for 5 minutes at 500 rpm. Cell pellets were then gently 
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resuspended in 1X hypotonic buffer and incubated for 15 mins on ice. The cytoplasmic 
fraction was collected as the lysate following centrifuging for 30s at 14,000xg. The 
remaining cell pellet was further lysed in Complete Lysis Buffer, incubated on ice for 30 
mins at 150rpm and centrifuged for 10 minutes at 14,000xg to collect the nuclear 
fraction. The cytoplasmic and nuclear proteins were then separated by SDS-PAGE as 
previously described. 
 
2.2 Statistical analysis 
Statistical analyses were performed using Prism 6 software (GraphPad, San 
Diego, CA). Data represent the mean ± S.D. or ±SEM as indicated. A two-tailed 
Student’s t-test was used when comparing two means between groups as specified. All 

















CHAPTER 3: ASSESSING THE ROLE OF SERINE 15 PHOSPHORYLATION IN 
PRMT5-MEDIATED ACTIVATION OF NF-ĸB SIGNALING 
3.1 Background and Rationale 
Recently, PRMT5 has emerged as an important biomarker for several cancer 
types including CRC and its overexpression is highly correlated to the proliferative 
signaling which drives malignancy (B. Zhang et al., 2015). Importantly, the cancer-
associated properties of PRMT5 are mediated by its ability to methylate a variety of 
substrate proteins, among which are critical transcription factors that trigger the 
downstream signaling cascades necessary for cancer cell survival. Importantly, our 
previous work demonstrated that PRMT5 overexpression could substantially augment 
activation of the pro-inflammatory transcription factor NF-κB via methylation of R30 on its 
p65 subunit (Prabhu et al., 2017). Moreover, approximately 75% of NF-κB–dependent 
genes were induced less well upon overexpression of the R30A mutant compared to the 
wild type p65 protein. This finding is significant, since elevated activation of NF-κB and 
subsequent dysregulation of its downstream target genes is one of the key mechanisms 
involved in promoting the malignancy of CRC and thus, PRMT5 overexpression 
represents an important means by which this aberrant NF-κB activity could be achieved. 
However, the precise mechanisms governing this PRMT5/NF-κB signaling axis are 
largely unknown, yet this knowledge is critical for mitigating PRMT5-mediated activation 
of NF-ĸB.  
By means of mass spectrometric analysis of purified PRMT5, we identified a 
novel S15 phosphorylation site on PRMT5 in response to IL-1β stimulation. We therefore 
hypothesized that phosphorylation of PRMT5 at S15 mediates its ability to activate NF-
ĸB signaling. Here, we investigate the significance of S15 phosphorylation using an 
S15A-PRMT5 mutant, with respect to its role in the transactivation of NF-ĸB and 
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induction of downstream target genes. Mechanistically, we were also prompted to 
perform a series of experiments to further probe the role of S15 phosphorylation in 
regulating the methyltransferase activity of PRMT5, complex formation between PRMT5 
and p65 as well as the promoter occupancy of p65 at its classical target gene, IL8. 
Overall, the findings depicted in this chapter will not only enhance our understanding of 
the fine-tuned regulation of PRMT5, but will provide key insights into the factors 
underlying its specific activity towards p65, which may be of potential major significance 
in the context of cancers with elevated PRMT5 and NF-κB activities.  
 
3.2 Results 
3.2.1 Identification of serine 15 (S15) phosphorylation site on PRMT5 
Phosphorylation of proteins remains one of the key mechanisms employed by 
cells to not only increase the functional diversity of the proteome but to ultimately 
influence various aspects of pathogenesis (Ardito et al., 2017). Using mass spectrometry 
approaches, we screened for potential phosphorylation modifications on PRMT5. First, 
we overexpressed Flag-tagged PRMT5 (Flag-PRMT5) in 293IL1R cells (denoted as 
HEK293) that were left untreated or stimulated with 10ng/mL of IL-1β. The 293IL1R cell 
line was previously described by Lu et al (Lu et al., 2010).  As shown in Figure 9, a 
mass shift of 80 Da was identified on Serine 15 (S15) of the Flag-PRMT5 protein purified 
(using an anti–Flag-M2 antibody) from IL-1β-treated HEK293 cells, corresponding to 
addition of a phosphorus group on this residue.  
 
3.2.2 Generation of stable cell lines with overexpression of Flag-WT and S15A-PRMT5     
To elucidate the biological role of S15 phosphorylation, we used a PCR-induced 
mutagenesis approach to successfully generate an S15A-PRMT5 mutant using a 
previously Flag-tagged WT-PRMT5 (Flag-WT) subcloned in a pLVX-IRES-puro vector as 
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the template (Lu et al., 2010). Next, as shown in the western blot of Figure 10A, we 
exogenously and stably overexpressed the Flag-S15A-PRMT5 mutant protein at a level 
comparable with Flag-WT in HEK293 cells and a panel of CRC cell lines HT29, DLD1 
and HCT116 using lentiviral plasmids and a 293T packaging cell line. The resulting 
stable cell lines were selected under puromycin (1μg/mL). The chosen CRC cell lines 
are well-established representative models widely used to investigate tumor biology and 
biomarker discovery. Importantly, they also harbor the genetic heterogeneity of many 
primary colorectal tumors, further validating their utility as tools to investigate CRC 
biology (J. Wang et al., 2017). The mutation status of the most common CRC-related 
genes identified in the aforementioned cell lines are outlined in Appendix F.  In the 
context of this study, we overexpressed the different forms of the PRMT5 protein as a 
means of investigating the observable effect of modulating a single factor on a range of 
phenotypes. Since endogenous PRMT5 is still present in these cells, future experiments 
to first deplete PRMT5 using 3’-UTR shRNA approaches followed by addback of the WT 
and S15A-PRMT5 proteins was preferential. Although not used in the present study, the 
most ideal scenario would be to employ CRISPR-Cas9 knock-in of the S15A-PRMT5 at 
the relevant locus to avoid any potential confounding influences of endogenous PRMT5 
expression. Experiments described in this and subsequent sections were conducted 
using a pool of early passage stable cells frozen down at -80°C and where applicable, 
HT29 was used as a representative CRC cell to confirm mechanistic studies carried out 
in HEK293 cells.   
Further validation of whether S15 phosphorylation constitutes a major serine 
phosphorylation site on PRMT5 was conducted by immunoprecipitation of Flag-WT-
PRMT5 or Flag-S15A-PRMT5 followed by western blotting with a pan serine 
phosphorylation (pSER) antibody. This approach was used due to unavailability of an 
S15 site-specific antibody. As revealed in Figure 10B, upon treatment of HEK293 and 
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HT29 with IL-1β, the immunoprecipitated Flag-WT was phosphorylated, whereas the 
Flag-S15A-PRMT5 mutant exhibited dramatically less serine phosphorylation, 
suggesting that S15 is a major phosphorylation site on PRMT5. Furthermore, alignment 
of PRMT5 sequences showed that this S15 site is well conserved across different 
species (Figure 10C).  
 
3.2.3 Phosphorylation of PRMT5 at S15 is critical for NF-ĸB activation 
We previously discovered that overexpression of PRMT5 could dramatically 
enhance the methylation status of p65 and in turn NF-ĸB activation, whereas knockdown 
showed the opposite effect (Wei et al., 2013). Furthermore, based on the findings thus 
far in Figures 9 and 10, we found S15 phosphorylation to be an IL-1β-inducible event 
and hence, we further speculated that it may potentially mediate the activation of NF-κB 
by PRMT5. Through a complex cascade of combinatorial phosphorylation and 
ubiquitination events, IL-1β acts as a potent activator of NF-κB and its related 
intracellular signaling events. Hence, using our established cell lines overexpressing 
WT-PRMT5 or the S15A-PRMT5 mutant, we assessed the activation of NF-κB using a 
luciferase reporter assay that involves lentiviral-based infection of our cells with a 
p5XIP10 construct (containing five tandem copies of the ĸB elements of the IP10 gene 
promoter upstream of the firefly luciferase reporter gene) followed by addition of the 
substrate, luciferin, 48 h after infection. As shown in Figure 11, we confirmed that 
overexpression of PRMT5 could significantly augment NF-κB activity in an IL-1β-
inducible manner compared to the vector control (Ctrl), whereas in HEK293, HT29, 
DLD1 and HCT116 S15A-PRMT5 -expressing cells, NF-κB was less activated.  This 
suggests that this phosphorylation site is important to PRMT5-mediated NF-κB 
transactivation and may also potentially mediate more downstream signaling effects.  
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Finally, we also observed that in the presence of endogenous PRMT5, the S15A-
PRMT5 mutant decreased the activation of NF-κB to a level comparable or below that of 







Figure 9:  Identification of phosphorylation of Serine 15 (S15) on PRMT5. Top panel, 
mass spectrometry (MS) experiment identifies S15 as a phosphorylated residue in 
response to IL-1β treatment. A mass shift of 80Da was observed, indicating the 
existence of the phosphorylation modification. Bottom panel, Gel-code blue stained MS 
gel indicates a purified strong Flag-PRMT5 protein band (left). Western analysis 






    
Figure 10: Establishment of wild type (WT) or Serine 15 to Alanine (S15A) mutant Flag-
PRMT5 overexpressing stable cells. A. Western blot images, showing overexpression of 
Flag-PRMT5 constructs probed with anti- PRMT5, or Flag, or -actin respectively, in 
HEK293 cells or HT29, DLD1 and HCT116 colon cancer cells. B. Confirmation of 
phosphorylation of PRMT5 at S15 using co-immunoprecipitation and western blot 
analysis. Either HEK293 (top panel) or HT29 cells (bottom panel) were treated with IL-1β 
or left untreated for 1 h (10 ng/mL). Samples were collected and Flag-WT-PRMT5 (Flag-
WT) or Flag-S15A-PRMT5 (Flag-S15A) was further immunoprecipitated with anti-Flag-
M2 beads and subjected to western analysis using an anti-phospho-serine motif 
antibody (pSER). The inputs were probed with anti-PRMT5 antibody. C. Cross-species 
alignment of amino acid sequences from PRMT5 proteins (residues 1-60). The 






















Figure 11: Phosphorylation of PRMT5 at S15 is critical for NF-ĸB activation in response 
to IL-1β. A. Phosphorylation of PRMT5 at S15 is critical for NF-ĸB activation. NF-κB 
luciferase assay, conducted for vector control (Ctrl), or with the stable overexpression of 
WT-PRMT5 (WT) or S15A-PRMT5 (S15A) in the presence or absence of 10 ng/mL IL-1β 
treatment in HEK293, and HT29, DLD1, HCT116 colon cancer cells. Readings were 
normalized to total protein concentration for respective wells. *p<0.05 vs. Ctrl+IL-1β 




















3.2.4 Phosphorylation of PRMT5 at S15 differentially regulates a subset of NF-κB target 
genes 
Next, we simultaneously sought to assess whether the transcriptional levels of 
NF-κB target genes could be upregulated by PRMT5 overexpression and compromised 
by the S15A-PRMT5 mutant, which are downstream events of the afore-mentioned 
phospho-mediated transactivation of NF-κB by PRMT5. This is also based on our 
previous finding in which the R30A mutant of p65 and knockdown of PRMT5 could in 
parallel, downregulate a significant fraction of NF-κB-dependent genes (Wei et al., 
2013). To initially test our hypothesis that S15A-PRMT5 would disrupt NF-κB target gene 
transcription, HEK293 cells with or without (Ctrl) WT-PRMT5 or S15A-PRMT5 
overexpression, in the presence or absence of IL-1β were used to carry out Illumina 
microarray analysis. This work was done in collaboration with Dr. Pieter Faber at the 
University of Illinois at Chicago. We observed that of the pool of IL-1β-inducible genes, 
approximately 48% were further upregulated 1.5-fold or more by overexpression of WT-
PRMT5 compared to the vector control (WT+IL-1β/Ctrl+IL-1β≥1.5 fold) (Figure 12A, left 
pie chart). However, when compared to these WT-PRMT5-upregulated transcripts, 
approximately 39% of this subset of genes failed to be upregulated in the cells 
overexpressing the S15A-PRMT5 mutant protein (S15A-PRMT5 + IL-1β/WT+ IL-1β≤0.5 
fold) (Figure 12A, right pie chart).  
Intriguingly, we uncovered that among the genes that were upregulated by the 
WT-PRMT5 but not S15A-PRMT5, were a range of cytokines (e.g., TNFα), chemokines 
(IL8, CCL20, CXCL10), and cell adhesion molecules (e.g., E-selectin, VCAM-1), all 
components implicated in CRC initiation and progression. A short list of typical genes 
whose induction was inhibited by the S15A mutation is shown in Figure 12A (table) and 
a full list is provided in Appendix E. Confirmation of the array data by qRT-PCR analysis 
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consistently showed that the mRNA transcript levels of candidate genes CCL20 and IL8 
were further augmented by the overexpression of PRMT5 in both HEK293 and HT29 
under IL-1β-stimulating conditions whereas overexpression of S15A-PRMT5 significantly 
attenuated this effect (Figure 12B). In a cross comparison, we also found that several of 
these genes including IL8 and CCL20 were among those downregulated by the 
previously reported R30A mutation of p65 (Table 2), suggesting a correlation between 
S15 phosphorylation (of PRMT5)  ̶and R30 methylation (of p65)  ̶dependent gene 
regulation.  
 Collectively, these data strongly support the notion that overexpression of 
PRMT5 can augment the NF-ĸB signaling at many levels in an IL-1β-inducible and 
phospho-dependent fashion. Importantly, phosphorylation of S15 on PRMT5 plays a 
critical role in the IL-1β-inducible expression of a subset of NF-κB target genes whose 



































Figure 12: Phosphorylation of PRMT5 at S15 differentially regulates a subset of NF-κB 
target genes. A. Top panel: Pie-char (left, yellow and orange), representing data from 
human Illumiona array assay. Data indicates that upon overexpression of WT-PRMT5, 
the expression of 48.31% of NF-ĸB target genes were further augmented by >= 1.5-fold 
following 10 ng/mL IL-1β stimulation. Among these genes, 39.15% of genes (Pie-chart, 
right, gray and blue) could be downregulated by 2-fold or more (S15A + IL-1β/WT+IL-
1β≤0.5) by the S15A-PRMT5 mutation. Bottom panel: Table, showing a short list of 
typical NF-ĸB target genes that were upregulated by WT-PRMT5 (WT) but not by the 
S15A-PRMT5 mutant. B. Confirmation of Illumina Array data with qPCR analysis, 
indicating relative mRNA levels of CCL20 and IL8. Ctrl: vector control cells. †p<0.05 vs. 




3.2.5 Top diseases and biological functions regulated by S15 
To identify the signature biological functions and networks associated with the 
subset of genes differentially regulated by S15A-PRMT5, we further conducted an 
ingenuity pathway analysis (IPA) in collaboration with Drs. Guanglong Jiang and 
Yunlong Liu of the IUSM Center for Computational Biology and Bioinformatics. 
Interestingly, we observed an enrichment of terms associated with key biological 
functions such as “migration of tumor cells”, “proliferation of tumor cells” and “colony 
formation”. Moreover, networks related to “cancer” and “development disorders” were 
among the top enriched disease networks while IL-1β, IKBKB and the NF-ĸB complex 
were by far the most highly enriched upstream pathway regulators (Figure 13A). 
Interestingly, representative networks revealed NF-ĸB as a key interaction node among 
the genes upregulated by WT-PRMT5 and compromised by the S15A-PRMT5 mutant 
































Figure 13: Top diseases and biological functions regulated by S15A-PRMT5. A. Subset 
of genes upregulated by WT-PRMT5 overexpression but downregulated by S15A-
PRMT5 was used to perform Ingenuity Pathway Analysis (IPA). Enrichment results 
indicating top biological functions, disease networks and upstream regulators as shown 
in dots scaled by–log(p). The size of the dot shows the significant level of enrichment. B. 
IPA representative network showing genes regulated by S15A-PRMT5 with NF-κB as 





Table 2: Genes commonly regulated by S15A-PRMT5 and R30A-p65  
 
Gene Symbol Description   
CCL20 C-C Motif Chemokine Ligand 20 
CXCL2 C-X-C Motif Chemokine Ligand 2 
DMRT2 Doublesex And Mab-3 Related Transcription Factor 2 
ESM1 Endothelial Cell Specific Molecule 1 
IL32 Interleukin 32 
IL8 Interleukin 8 
MAFF MAF BZIP Transcription Factor F 
MAP3K8 Mitogen-Activated Protein Kinase Kinase Kinase 8 
NFKBIZ Nuclear Factor Kappa B Inhibitor Zeta 
PTGS2 Prostaglandin-Endoperoxide Synthase 2 
SELE Selectin E 
TM6SF2 Transmembrane 6 Superfamily Member 2 
TNFAIP3 TNF Alpha Induced Protein 3 











3.2.6 S15A-PRMT5 disrupts formation of the complex between PRMT5 and p65 
Post-translational modifications play pivotal roles in governing the function of 
proteins, in part by mediating important protein-protein interactions and the assembly of 
larger multi-protein complexes. We therefore hypothesized that a possible 
phosphoserine-dependent complex formation between PRMT5 and p65 may place it into 
close proximity with PRMT5, where it becomes a target for symmetric dimethylation. 
Hence, to further explore the possible mechanisms underlying the negative regulation of 
NF-ĸB activity by S15A-PRMT5, we wondered whether this mutant altered the PRMT5-
p65 complex formation and thus could indirectly impair the downstream R30 
methylation-regulated transcriptional competence of p65. As shown in Figure 14 and 
consistent with our previous findings (Wei et al., 2013), co-immunoprecipitation studies 
of Flag-WT-PRMT5 purified from cells pre-treated with IL-1β showed an enhanced 
complexing between PRMT5 and endogenous p65 in both HEK293 and HT29 cells. 
Conversely, the immunoprecipitated Flag-S15A-PRMT5 complexed less well with p65, 




































Figure 14: S15A mutant of PRMT5 disrupts its complex with p65. Co-
immunoprecipitation (IP) experiments, HEK293 and HT29 cells were treated or left 
untreated with IL-1β (10ng/mL) for 1 h, Flag-WT-PRMT5 (Flag-WT) or Flag-S15A-
PRMT5 (Flag-S15A) was immunoprecipitated with anti-Flag-M2 beads. Samples were 
then subjected to western blot analysis (WB) and probed with anti-p65 antibody. Inputs 








3.2.7 S15A-PRMT5 attenuates occupancy of p65 at NF-ĸB target gene 
Considering the positive and negative contribution of WT-PRMT5 and S15A-
PRMT5 to NF-ĸB downstream target gene activation, respectively, we next asked 
whether this was associated with differential binding and occupancy of p65 at the 
promoter of its target genes. To provide support for this hypothesis, we were prompted 
to conduct ChIP-PCR analysis to determine the proximal promoter occupancy of p65 at 
the IL8 gene, a prototypical target gene of NF-ĸB that harbors a ĸB element in its 
promoter (Figure 15A). Moreover, this gene was also confirmed as S15A-PRMT5 -
regulated using our earlier microarray and qPCR studies (Figure 12).  Interestingly, 
overexpression of PRMT5 led to a strikingly enhanced occupancy of p65 at the IL8 
promoter along a time course treatment with IL-1β in both HEK29 and HT29 cells 
(Figure 15B). On the other hand, the IL-1β-induced p65 promoter occupancy was 
substantially reduced by S15A-PRMT5, demonstrating that S15 phosphorylation 








Figure 15: S15A mutant of PRMT5 attenuates occupancy of p65 at NF-ĸB target gene, 
IL8. A. Architecture of the IL8 promoter showing location of the NF-ĸB binding site. B. 
Chromatin immunoprecipitation (ChIP) assay in HEK29 and HT29 cells to detect 








3.2.8 S15 phosphorylation regulates IL-1β-inducible PRMT5 methyltransferase activity 
Based on the domain architecture of human PRMT5, we determined that the S15 
residue is located within the unique N-terminal triosephosphate isomerase (TIM)-Barrel 
(Figure 16A). Interestingly, several studies suggest that contributions from the TIM-
Barrel may potentially control various aspects of PRMT5’s function including its 
oligomerization state, substrate specificity and enzymatic activity. We therefore 
reasoned that phosphorylation of PRMT5 at S15 could influence one or more of the 
properties assigned to this structural region, such as its intrinsic methyltransferase 
activity and in turn, this could affect its activity towards NF-ĸB. To test this notion, we 
immunoprecipitated enzyme preps of Flag-WT-PRMT5 and Flag-S15A-PRMT5 from 
HEK293 cells that were left untreated or stimulated with IL-1β. As a negative control, we 
also generated and purified Flag-PRMT5 containing a glutamate-to-aspartic mutation at 
E444 (Flag-E444D), an invariant glutamate residue within the active site previously 
reported as being critical to its methyltransferase activity. Hence, Flag-E444D was used 
to represent an enzymatically dead mutant of PRMT5. We then employed our previously 
described AlphaLISA assay (Prabhu et al., 2017) to compare the specific activity of Flag-
WT, Flag-S15A-PRMT5  and Flag-E444D using an H4R3 peptide as a substrate.  
As shown in Figure 16B, IL-1β treatment significantly enhanced the activity of 
WT-PRMT5 while S15A-PRMT5 showed significant attenuation of this ligand-induced 
activity. Intriguingly, there was no significant difference between the activity of the WT 
and S15A-PRMT5 enzymes under basal conditions, suggesting a putative IL-1β-
dependent mechanism by which S15 phosphorylation induces conformational changes 
in such a way to enhance PRMT5’s activity albeit other factors are also likely at play 
since this enzymatic activity was not completely abolished by S15A-PRMT5. One 
limitation of the AlphaLISA technique is that the acceptor beads used in the assay are 
conjugated to an antibody that specifically recognizes the H4R3me2s mark and so while 
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ideally, we would have liked to use p65 as a substrate for this experiment, the necessary 
reagents were not readily available. Alternatively, we collaborated with Genescript to 
generate a customized antibody that recognizes R30 symmetric dimethylation of p65 
(p65-R30me2s). Since differential PRMT5 activity could impact the R30me2s status of 
p65, we conducted western blot analyses to detect this methylation in WT-PRMT5 
versus S15A-PRMT5 -overexpressing HEK293 cells. As predicted, we observed that the 
S15A-PRMT5 -overexpressing cells showed less IL-1β-inducible p65-R30me2s levels 
compared to the WT (Figure 16C), further reiterating the critical role of S15 
phosphorylation in regulating the activity of PRMT5 towards p65.  
 
3.2.9 S15A-PRMT5 does not alter the subcellular localization of PRMT5  
Phosphorylation has been frequently shown to regulate the localization of 
modified proteins. We therefore wondered whether the reduced PRMT5/p65 complex 
formation and attenuated transactivation of p65 conferred by the S15A-PRMT5 mutant 
may be due to other factors such as altered subcellular localization of S15A-PRMT5 
compared to WT-PRMT5.  We therefore carried out cell fractionation assays to 
determine the impact of the S15A-PRMT5 mutant on the cytoplasmic and nuclear 
localization of PRMT5. Qualitatively, no appreciable difference in the subcellular 
compartmentalization pattern of the WT-PRMT5 and S15A-PRMT5 proteins was 
observed, indicating that the cytoplasmic-nuclear distribution of PRMT5 was not 














Figure 16: S15 phosphorylation is located within the TIM barrel domain of PRMT5 and 
regulates IL-1β-inducible PRMT5 methyltransferase activity. A. Overview of the domain 
architecture of human PRMT5. The S15 residue is located in the unique N-terminal TIM-
Barrel, which might be critical for PRMT5 substrate binding. B. S15 phosphorylation is 
critical for the methyltransferase activity of PRMT5. AlphaLISA assay was conducted by 
using biotinylated histone H4 as a PRMT5 substrate. Graph shows detection of specific 
methyltransferase activity of WT-PRMT5 (WT) or S15A-PRMT5 (S15A) mutant enzymes 
purified from HEK293 cells in the presence or absence of IL-1β (10ng/mL) treatment. 
E444D-PRMT5 (E444D) was used as an enzymatic dead mutant control. S-adenosyl 
methionine (SAM) was used as the methyl donor for the reaction. The data represent the 
means ± standard deviation (S.D.) for three independent experiments. *p<0.05 vs. WT 
group; #p<0.05 vs. WT+IL-1β group.  C. Western blot image, showing symmetric 
dimethylation of arginine 30 of p65 (p65-R30me2) in Flag-WT-PRMT5 and Flag-S15A-
PRMT5 in the presence or absence of IL-1β (10ng/mL) treatment. Blot was probed with 






3.2.10 S15A-PRMT5 acts independently of IĸBα degradation and p65 nuclear 
translocation 
In resting cells, the p65/p50 heterodimer of NF-ĸB is retained in the cytoplasm 
through its complex with IĸBα.  Upon activation with stimuli such as IL-1β, canonical NF-
ĸB signaling involves various critical steps including the phosphorylation, ubiquitination, 
and subsequent proteasomal degradation of IκBα, which leads to the nuclear 
translocation of the p65/p50 subunits followed by DNA binding, and gene 
transcription. We therefore speculated that S15A-PRMT5 could alter the degradation of 
IĸBα in response to IL-1β and thus potentially impair p65 translocation to the nucleus. To 
test this possibility, we treated HEK293 cells with a timecourse of IL-1β wherein we 
would expect rapid ligand-induced IĸBα degradation which eventually becomes 
resynthesized. As shown in Figure 17B, no significant difference in the IĸBα degradation 
pattern was observed between the control, WT-PRMT5- and S15A-PRMT5 -expressing 
cells. Moreover, no qualitative difference in the translocation of p65 to the nucleus was 
detected in our fractionation experiments conducted using the same cells (Figure 17A), 
indicating that S15A-PRMT5 may be acting independently of these mechanisms. To 
provide a more complete picture, future experiments to determine the effect of the R30A 


















Figure 17: S15A-PRMT5 does not alter subcellular localization of PRMT5 and acts 
independently of IĸBα degradation and p65 nuclear translocation. A. Cell fractionation 
assay, showing subcellular compartmentalization of Flag-PRMT5 in HEK293 cells. 
Western blot was probed with anti-Flag, p65, LaminB1 and α-tubulin antibodies. B. 
Western blot, showing IL-1β-induced IĸBα degradation pattern in control, WT-PRMT5 










3.3 Summary and Discussion  
A wealth of reported findings supports the essential biological functions of 
PRMT5 in a plethora of cellular processes including proliferation, transcriptional 
activation/repression, signal transduction and cell differentiation.  Due to its important 
role in these processes, PRMT5 has emerged as a critical biomarker for a variety of 
human cancers, including CRC and its frequent overexpression is implicated in driving 
cancer signaling, growth and survival (Shailesh et al., 2018). The cancer-associated 
properties of PRMT5 are mediated by its symmetric dimethylation of both histone and 
non-histone substrates which in turn trigger the downstream oncogenic signaling 
cascades necessary for malignancy. Unfortunately, little is known about the underlying 
mechanisms that fine-tune PRMT5’s activity and/or involvement in these signaling axes, 
yet this knowledge is critical since these mechanisms form the basis for devising rational 
therapeutic strategies for targeting PRMT5. In this regard, accumulating studies 
demonstrate that PRMT5 can be regulated by posttranslational modifications such as 
phosphorylation.  
In the present study, we report a novel S15 phosphorylation event on PRMT5 in 
response to IL-1β stimulation. Based on our previous discovery that overexpression of 
PRMT5 plays a role in enhancing IL-1β-induced NF-κB-mediated transcriptional 
responses through R30 methylation of the p65 subunit of NF-κB, we postulated that this 
phosphorylation event may positively regulate this important PRMT5/NF-ĸB signaling 
axis. First, we found that S15 phosphorylation was important for the IL-1β-inducible 
transactivation of p65 by PRMT5 and downstream activation of a subset of NF-ĸB target 
genes associated with distinct cancer-related gene networks. Second, we established 
that mechanistically, the S15A-PRMT5 mutant decreased the activation of NF-ĸB 
signaling by attenuating the complex between PRMT5 and p65 and compromising the 
promoter occupancy of p65 at its target gene, IL8. Moreover, overexpression of S15A-
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PRMT5 correlated with reduced R30 methylation of p65, suggesting that S15 
phosphorylation may act as a crucial intermediate for the enhanced NF-ĸB response 
observed with PRMT5 overexpression. Third, using an in vitro-based AlphaLISA assay, 
we uncovered for the first time that IL-1β could enhance the methyltransferase activity of 
PRMT5 which was reduced by the S15A-PRMT5 mutant. These findings support a 
complex model of the regulation of PRMT5 by serine phosphorylation that define both 
methyltransferase activity, protein-protein interactions as well as expression of NF-ĸB-
regulated gene signatures. 
Phosphorylation is a potent regulatory mechanism of protein function and is 
arguably the most commonly studied PTM. In eukaryotes, it is a highly dynamic process 
that involves the kinase-catalyzed covalent attachment of a negatively charged 
phosphate group to mainly serine, threonine and tyrosine residues, which can be 
removed by the action of phosphatases. Importantly, this PTM significantly modifies the 
function of proteins by inducing conformational changes and offers a dynamic way to 
regulate subcellular localization, protein stability and enzymatic activity. Additionally, it 
can mediate interactions between the phosphorylated protein and a range of binding 
partners, thus generating phospho-dependent protein signaling networks. Oftentimes, 
these phospho-dependent interactions are signal-induced. Here, we identified the IL-1β-
inducible phosphorylation of PRMT5 at S15 as positively modulating its complexing with 
p65. Considering the spectrum of PRMT5 target proteins and binding partners, the 
factors driving its interaction with one protein or another is innately complex and 
contextual. However, it is reasonable to consider that S15 phosphorylation may act to 
either confer discriminatory specificity towards p65 or trigger its complex with other 
substrates or even other proteins of the PRMT5 interactome in a context- and perhaps 
cell-type-dependent manner. In fact, recent evidence suggests that phosphorylation of 
PRMT5 may endow specificity in its interactions. For instance, Espejo et al 
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demonstrated that phosphorylation of threonine sites within the C-terminal tail of PRMT5 
favored a phospho-dependent interaction with 14-3-3 over PDZ-domain-containing 
proteins, thus generating an interaction switch (Espejo et al., 2017). Furthermore, 
several reports suggest that among the larger multimeric complexes that PRMT5 
associates with, are various cofactors and adaptor proteins such as MEP50/COPR5 and 
RioK1, respectively. Under different contextual clues, these interacting partners can 
determine the substrate selection of PRMT5 such as its preferential methylation of 
histones versus other target substrates. Hence, further studies to elucidate whether S15 
phosphorylation is important for PRMT5’s interaction with other cofactors, adaptor 
proteins or substrates beyond p65 are warranted.  
Other PTMs have been shown to influence other aspects of PRMT5 function, 
including its oligomerization state and methyltransferase activity. Nie et al showed that 
CARM1-mediated asymmetric dimethylation of PRMT5 enhanced its methyltransferase 
activity by promoting its dimerization (Nie et al., 2018). Similarly, Lattouf et al identified 
LKB1-mediated threonine phosphorylation as being important in enhancing its activity by 
regulating its cofactor protein interaction (Lattouf et al., 2019).  Interestingly, the work 
outlined in this chapter is of great import in that it has established a novel mechanism of 
enhancing PRMT5 methyltransferase activity via IL-1β-mediated serine phosphorylation 
which constitutes another layer of unique contribution to the field. The significance of this 
finding is further reinforced by the critical link between IL-1β-mediated S15 
phosphorylation, enhanced PRMT5 activity and increased NF-κB activation. IL-1β is 
frequently secreted by cells in the tumor microenvironment and serves as a potent 
activator of pro-inflammatory signaling. Hence, our data supports a model in which this 
PRMT5/NF-κB signaling node is activated by IL-1β to potentially promote inflammation 
and tumor invasiveness. In the future, we would like to further explore this exciting 
possibility using physiologically relevant and well-defined tumor microenvironment 
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models. It is also important to acknowledge that other cytokines and signaling molecules 
such as TNF-α can activate NF-κB and thus we cannot rule out the possibility that these 
molecules could also induce phosphorylation of PRMT5 and thus converge on 
PRMT5/NF-κB signaling. Future studies are needed to tease out these intricacies.   
Recent knowledge regarding the known structural features of PRMT5 may 
provide critical insight into the catalytic and protein-protein interacting regulatory roles of 
S15 phosphorylation. Like other PRMTs, PRMT5 contains a catalytic domain, the 
Rossmann-fold, which interacts with the methyl donor SAM and is highly conserved 
between the Caenorhabditis elegans (C. elegans), Xenopus laevis (X. laevis) and 
Human isoforms of PRMT5. At the C-terminus is the β-barrel which contains a 
dimerization domain important for the formation of multimeric complexes. At the N-
terminus is the TIM barrel, which is unique to PRMT5. This domain has been primarily 
implicated in promoting PRMT5 oligomerization and recruitment of cofactors such as 
MEP50 (S. Antonysamy, 2017). Additionally, the TIM barrel serves as a scaffold for the 
binding of adaptor proteins, such as pICLn and RioK1, which dictates whether PRMT5 
methylates Sm proteins or nucleolin, respectively (Guderian et al., 2011). Hence, this 
domain is important for the assembly of PRMT5 complexes and their subsequent 
substrate specificities. Intriguingly, recent studies provide new evidence that the TIM 
barrel is also critical to regulating the catalytic activity of PRMT5. The catalytic activity of 
a mutant human PRMT5 lacking the N-terminal region encompassing the TIM-barrel 
domain was shown to be severely compromised, suggesting that the TIM-barrel domain 
has other essential functions in addition to being important for PRMT5 dimerization and 
substrate selectivity (L. Sun et al., 2011). This is consistent with other reports that 
demonstrated that residues within the TIM barrel of several TIM barrel-containing 
enzymes were involved in the metal-ligation and phosphate-binding essential for 
catalysis (Nagano et al., 2002). Taken together, these findings have potentially 
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significant implications since the S15 residue is located within this TIM barrel region. 
This argues a possible regulatory role for S15 phosphorylation within this segment 
based on our preliminary evidence that this PTM may potentially affect some of the 
cellular and biochemical properties of PRMT5. So far, this is consistent with our data that 
shows the ability of this PTM to regulate the IL-1β-inducible catalytic activity of PRMT5 
which coincided with its complexing with, and subsequent dimethylation of p65 at R30.  
Finally, we elegantly showed that compared to the WT-PRMT5, overexpression 
of S15A-PRMT5 -PRMT5 correlated with reduced occupancy of p65 at the IL8 promoter 
which mechanistically explains the attenuated expression of IL8 previously observed by 
microarray and qPCR analyses.  We recognize that since p65 occupancy was not 
completely abrogated by the S15A-PRMT5 -PRMT5 mutant, we can infer the influence 
of S15 phosphorylation-independent mechanisms in mediating the recruitment of p65 to 
cognate promoter sequences. Moreover, future ChIP experiments are needed to 
determine if the afore-mentioned phenomenon is observed at other prototypical NF-ĸB 
target genes other than IL8. Finally, to corroborate our findings and provide further 
support for a phosphoPRMT5-mediated regulation of R30 p65 methylation model, it 
would also be interesting to see if we observe a similar reduction in the occupancy of 
p65 at the IL8 promoter in cells expressing the R30A mutant of p65 or with knockdown 
of PRMT5.  
 
3.4 Concluding Remarks 
In summary, this chapter is based on the hypothesis that phosphorylation of 
PRMT5 at S15 regulates the dimethylation, transactivation and target gene expression 
of NF-κB by facilitating phospho-dependent methyltransferase activity and formation of a 
complex between PRMT5 and p65. Moreover, it has become increasingly clear that 
PRMT5 is phosphorylated at several residues, including S15. However, whether these 
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modifications act as a universal or cell-type dependent regulatory phenomenon is still 
unknown and warrants further investigation. Finally, our discovery of this novel phospho-
dependent PRMT5 interaction with p65 suggests that crosstalk between kinases and 























CHAPTER 4: ASSESSING THE FUNCTIONAL ROLE OF SERINE 15 
PHOSPHORYLATION OF PRMT5 IN CRC CELLS 
4.1 Background and Rationale 
The multifaceted role of PRMT5 within many biological contexts naturally causes 
its deregulation to be implicated in a variety of cancers, including CRC. Although 
inhibition of PRMT5 holds great therapeutic potential, there is still a significant 
knowledge gap concerning the underlying mechanisms that contribute to its cancer-
associated properties. In this regard, our discovery that PRMT5 is regulated by S15 
phosphorylation and that this distinct PTM is essential to its activation of the major pro-
survival NF-κB pathway is highly significant.  Sustained activation of NF-ĸB is observed 
in 50-60% of CRC cases, and is increasingly recognized as a crucial player in many of 
the steps of disease progression and thus, phospho-dependent PRMT5-mediated 
activation of NF-ĸB represents one potential mechanism utilized by cancer cells to 
maintain growth and survival. We provided further support for this notion in a recent 
study from our lab which revealed that along with its established role in augmenting NF-
ĸB signaling, overexpression of PRMT5 could substantially enhance the anchorage-
independent growth, proliferative and migratory capabilities of CRC cells while 
knockdown had the opposite effect (Prabhu et al., 2017).  
Interestingly, our IPA data (Chapter 3) also revealed that genes significantly 
augmented by PRMT5 overexpression but compromised by S15A-PRMT5 were 
associated with an enrichment of the terms “migration of tumor cells”, “proliferation of 
tumor cells” and “colony formation”. Collectively, this led us to hypothesize that the 
S15A-PRMT5 mutant protein could in part, impair the tumor-promoting functions exerted 
by PRMT5 in CRC.  In this chapter, we investigate the functional significance of 
phosphorylation of PRMT5 at S15 in the context of CRC as it relates to these typical 
cancer phenotypes. The work presented here will provide key insight into one 
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potential mechanism by which PRMT5 contributes to CRC, with implications for other 
cancer types with elevated PRMT5 expression and/or activity.  
 
4.2 Results 
4.2.1 S15 phosphorylation mediates CRC cell growth associated with overexpression of 
PRMT5 
Compared to their benign counterparts, unchecked proliferation is a hallmark 
feature of cancer cells (Fouad et al., 2017). Previously, we showed that overexpression 
of PRMT5 could significantly enhance the proliferative capabilities of CRC cells while 
knockdown or pharmacological inhibition of PRMT5 had the opposite effect (Prabhu et 
al., 2017). Moreover, our IPA data suggested that S15A-PRMT5 -downregulated genes 
were implicated in proliferation-associated biological functions. To test the effect of the 
S15A-PRMT5 mutant on CRC cell growth, cells overexpressing the WT- or S15A- 
PRMT5 proteins were seeded in triplicate in 6-well plates and assessed for growth over 
a period of 9 days of culture. As shown in Figure 18, overexpression of WT-PRMT5 had 
a growth-enhancing effect compared to the control, recapitulating our previous findings. 
Conversely, overexpression of S15A-PRMT5 attenuated growth compared to WT, 
strongly suggesting that the enhanced proliferative capacity of CRC cell associated with 
overexpression of PRMT5, is at least in part, a phospho-mediated process.  
 
4.2.2 S15 phosphorylation mediates CRC cell anchorage-independent growth 
associated with overexpression of PRMT5 
Cancer-derived cells are able to survive and form colonies suspended in agar in 
the absence of anchorage to the extracellular matrix (ECM) and neighboring cells, a 
phenomenon termed anchorage independence of growth (Stoker et al., 1968). This 
unique property of cancer cells has been routinely used to identify tumors with invasive 
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and metastatic potential since it presumably reflects the tendency of tumor cells to 
survive and grow in inappropriate locations in vivo (Mori et al., 2009). Here, we tested 
whether the S15A-PRMT5 mutant could affect the extent of colony formation in CRC cell 
lines. WT-PRMT5-overexpressing cells showed a significant increase in both the size 
and number of colonies formed whereas the S15A-PRMT5 -overexpressing cells formed 
less and significantly smaller colonies (Figure 19), confirming that the role of PRMT5 in 
promoting anchorage-independent CRC cell growth is at least in part, dependent on S15 
phosphorylation. 
 
4.2.3 S15 phosphorylation mediates CRC cell migration associated with overexpression 
of PRMT5 
Compared to normal cells, cancer cells have an increased ability to migrate, 
another feature vital for tumor invasion and metastasis (Fouad et al., 2017). To validate 
the role of S15 phosphorylation in regulating the migratory potential of CRC cells, we 
used a Boyden chamber consisting of 8μm pore size cell culture inserts in a 24 well plate 
(H. C. Chen, 2005). Control, WT or S15A-PRMT5 -overexpressing cells were seeded in 
the top of the insert in serum-free media while serum-rich media was supplied as a 
chemoattractant to lower chamber. After 48h, migrated cells were fixed, stained with 
crystal violet, visualized and counted. Consistent with previous findings, the 
overexpression of WT-PRMT5 resulted in a significant increase in the number of 
migrated cells whereas overexpression of the S15A-PRMT5 mutant had the opposite 
effect (Figure 20), implicating S15 phosphorylation as being critical to the tumor invasive 





4.2.4 S15A-PRMT5 compromises secretion of cytokines and chemokines 
Within the tumor microenvironment, pro-inflammatory factors secreted by cancer 
and immune cells serve as important factors to promote the tumor stemness, 
proliferation invasion and migration necessary for disease progression (Setrerrahmane 
et al., 2017). Growing evidence suggests that PRMT5 plays an important role in 
regulating the expression of a number of these factors including several cytokines and 
chemokines (Harris et al., 2014; Harris et al., 2016; Richard et al., 2005).  Moreover, 
from our microarray data (Chapter 3), we also found that many of these factors are 
among the NF-ĸB target genes regulated by phosphorylation of PRMT5 at S15. To test 
the effect of S15A-PRMT5 on the secretion of these factors, we collected conditioned 
media from HT29 cells overexpressing the WT- or S15A-PRMT5 protein. We then used 
a Human Cytokine ELISA Array to determine the relative levels of a panel of secreted 
cytokines, chemokines and growth factors.   
Compared to the control and WT-PRMT5-overexpression counterparts, S15A-
PRMT5 cells compromised the secretion of a fraction of the 
cytokines/chemokines/growth factors tested, with some factors showing a more dramatic 
reduction than others (Figure 21). This further supports the notion that phosphorylation 
of PRMT5 at S15 regulates a subgroup of genes, among which are several confirmed 
NF-ĸB target genes including TNFα, interferon gamma-induced protein 10 (IP-10) and 
interleukin-4 (IL-4). Importantly, the upregulation of these cytokines has been linked to 
modulating inflammation, cancer cell proliferation, migration and angiogenesis, lending 
further credence to the role of S15 phosphorylated of PRMT5 in partially facilitating 
some of functions of PRMT5 in these processes.  
Taken together, these data demonstrate the important role of S15 
phosphorylation in regulating the cancer-associated functions exerted by PRMT5. This 
knowledge has provided deeper insight into some of the underlying mechanisms 
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involved in deregulation of PRMT5 and its potential link to CRC malignancy. One of our 
long-term goals is to translate our findings into a powerful diagnostic for identifying 
higher-risk patients based on molecular evidence supporting hyperactivation of this 
phospho-regulated PRMT5/NF-κB signaling node and into a survival benefit for patients. 
To facilitate this, future efforts to develop a highly specific antibody that recognizes the 







Figure 18: S15 phosphorylation mediates CRC cell growth associated with PRMT5 overexpression. Cell growth assay compares cell 
numbers of vector Ctrl, WT-PRMT5 (WT) or S15A-PRMT5 (S15A) mutant-overexpressing cells in HT29, DLD1 and HCT116 colon 
cancer cells. 2X104 cells were seeded and counted using a cell counting chamber at days 3, 5, 7 and 9. The data represent the 























Figure 19: S15 phosphorylation mediates CRC anchorage-independent growth 
associated with PRMT5 overexpression. Top panel: Anchorage-independent growth 
assay with colon cancer cells overexpressing WT-PRMT5 (WT) or S15A-PRMT5 (S15A) 
mutant compared to vector control (Ctrl). Representative images of colonies for HT29, 
DLD1 and HCT116 are shown. Bottom panel: Quantification of the average colony size 
and number is shown below the corresponding cell type. The data represent the means 
± standard deviation (S.D.) for three independent experiments. *p<0.05 vs. Ctrl group; 








Figure 20: S15 phosphorylation mediates CRC cell migration associated with PRMT5 
overexpression. Top panel: Boyden chamber transwell assay, showing migration of 
colon cancer cells overexpressing WT-PRMT5 (WT) or S15A-PRMT5 (S15A) mutant 
compared to vector control (Ctrl).  Representative photos of crystal violet stained cells 
are shown with 20X magnification. Bottom panel: Quantification of the average number 
of migrated cells is shown. The data represent the means ± standard deviation (S.D.) for 













Figure 21: S15 phosphorylation is important for cytokine and chemokine secretion. 
Analysis of cytokine expression in conditioned media from WT-PRMT5- or S15A-PRMT5 
-overexpressing HT29 cells using a Human Cytokine ELISA Array. Total of 32 














4.3 Summary and Discussion  
CRC is a leading cause of cancer-related mortality worldwide. One of the main 
challenges of treating CRC is the fact that is a highly heterogeneous disease, and 
besides standard chemotherapy and a few biologics, the availability of effective targeted 
treatment options for patients with advanced disease is quite limited. This indicates a 
clear unmet clinical need which continues to fuel interest for developing new approaches 
to prevent metastasis and inhibit tumor growth based on the molecular profile of CRC 
tumors, with the goal of improving prognosis for these patients. Aberrant activation of the 
transcription factor nuclear NF-ĸB is observed in 50-60% of CRC cases, and is 
increasingly recognized as a crucial etiological factor in many of the steps of cancer 
progression and chemotherapeutic resistance. Importantly, the ability of NF-ĸB to exert 
its pro-tumorigenic functions is often linked to its cooperativity with other cancer-
associated proteins. Recently, PRMT5 has emerged as an important biomarker for CRC 
malignancy and increasing evidence argues that enhanced expression of PRMT5 drives 
cancer cell growth and survival through its methylation of substrates involved in 
oncogenic signaling. Importantly, our lab identified a critical interplay between PRMT5 
and NF-κB with implications in cancer.  
In Chapter 3, we provided strong evidence that overexpression of PRMT5 in 
CRC cells significantly augmented the activation of NF-κB through symmetric 
dimethylation of p65 in an S15 phosphorylation-dependent manner. We then 
hypothesized that this phosphorylation event could contribute to promoting cancer-
associated characteristics accompanying overexpression of PRMT5 in part, by 
mediating activation of NF-κB. To this end, the work in this chapter demonstrated that 
when compared to wild-type PRMT5, the S15A-PRMT5 mutant significantly attenuated 
the growth, migratory and colony-forming abilities of CRC cells, thus establishing 
functional significance for this PTM. Although the list of PTMs that regulate PRMT5 has 
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grown over the last few years, insight into the biological relevance of these modifications 
is still significantly lacking. Furthermore, their relative importance in pathological contexts 
remains to be established and are governed by factors yet to be identified. In this 
respect, our findings have made a significant contribution to the field.  
As mentioned above, the tumor-associated properties of PRMT5 are mediated by 
its ability to methylate a number of key target proteins, including NF-κB. These PRMT5-
catalyzed modifications can coordinately trigger the necessary changes in gene 
expression programs that promote cancer malignancy. The majority of documented 
studies also show that the biomarker and therapeutic potential of PRMT5 in cancers 
such as CRC is based on its elevated levels in cancer tissues compared to normal or 
benign counterparts. In fact, the success of many targeted therapies is based on the 
identification of specific somatic mutations and/or upregulation of proteins that can be 
modulated as a means of selectively destroying cancer cells. These aberrations are 
often indicative of an evolved dependence on these oncogenic factors for sustained 
tumor growth. In the case of PRMT5 for instance, a recent comprehensive study on 
functional characterization of cancer cell dependencies revealed that loss of the 
metabolic enzyme methylthioadenosine phosphorylase (MTAP) conferred a selective 
dependence on PRMT5 (Kryukov et al., 2016). However, one caveat to consider is that 
PRMT5 is also essential for normal development and plays a critical role in cellular 
functions related to differentiation, spermatogenesis, hematopoiesis and splicing, among 
others. Therefore, while it is justified to develop potent mechanisms of inhibiting PRMT5 
in the treatment of CRC and other cancers, rigorous in vitro and in vivo testing should be 
done to rule out the potentially adverse effects that PRMT5 inhibition might have on 
other vital physiological processes. One way of addressing any undesirable deleterious 
toxicities associated with full inhibition of PRMT5 is to determine the optimal therapeutic 
range of dosing that will effectively destroy cancer cells with negligible effects on normal 
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cells. The use of nanoparticle-based targeted drug delivery represents another attractive 
strategy to accomplish selectivity. In the future, it may also be advantageous to identify 
possible combinatorial approaches that exploit synergistic vulnerabilities should these 
toxicities become clinically dose-limiting.  
Based on the findings presented in this chapter, we propose that overexpression 
of PRMT5 promotes some aspects of a malignant phenotype in CRC cells at least in part 
through its ability to enhance activation of NF-κB in an S15 phospho-dependent manner. 
We acknowledge however, that PRMT5-mediated signaling is inherently complex and 
NF-κB constitutes only one node in the possible range of signaling networks that 
phospho-PRMT5 might be acting through. Indeed, other PRMT5 substrates have been 
implicated in CRC including several histones and signaling factors such as EGFR, p53 
and E2F-1.  Thus, we cannot discount the possibility that the effects we observed with 
PRMT5 overexpression may be due to its direct or indirect regulation of these pathways. 
Moreover, due to its pleiotropic role, it is reasonable to assume that the contribution of 
NF-κB to the cancer phenotypes studied here may be exerted through both PRMT5-
dependent and independent mechanisms. Further studies to delineate these points are 
needed. The development of high-throughput approaches to determine global changes 
in the symmetric dimethylation status of PRMT5 target proteins in tandem with 
correlative transcriptome analyses will allow us to better define which PRMT5-driven 
pathways are active in a given tumor subtype. This will allow for a more rational design 
of therapies and identification of patient subsets that will likely benefit from targeting 
specific pathways. Finally, as new information about the cross-talk between PRMT5 and 
other tumor regulatory pathways in CRC becomes available, studies aimed at targeting 
multiple dependencies at once by evaluating the efficacy of combining existing FDA-
approved drugs with PRMT5 inhibitors should be considered.  
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4.4 Concluding Remarks  
In summary, the work described here has revealed an important regulatory 
mechanism by which PRMT5 exerts its tumor-promoting functions in CRC, via S15 
phosphorylation. This lends further support to the exploitation of PRMT5 as an important 
therapeutic target. Moreover, with the advent of multi-agent treatment modalities, it is 
critical to understand the mechanisms that govern cross-talk between various tumor-
promoting factors with the intent of determining whether these signaling networks confer 
certain susceptibilities to cancer cells. In this respect, our data has shed important light 
on the functional cooperativity between arginine methyltransferases and kinases that 
converge on the NF-κB pathway, uncovering another potential avenue of therapy for 
CRC which involves limiting the activity of the PRMT5/NF-κB axis using selective kinase 
















CHAPTER 5: PKCɩ PHOSPHORYLATES PRMT5 AND REGULATES PRMT5-
MEDIATED ACTIVATION OF NF-ĸB 
5.1 Background and Rationale 
Our collective findings from Chapters 3 and 4 demonstrate the potential to 
pharmacologically block the phosphorylation of PRMT5 using selective kinase inhibitors 
as the basis to disrupt PRMT5/NF-κB cooperativity and impede CRC growth.  Hence, 
the identification of the appropriate kinase mediating phosphorylation of PRMT5 at S15 
is of paramount importance in this process.  Using the human protein reference 
database (HPRD), we identified the S15 residue as having a high probability of being 
phosphorylated by PKC based on a compendium of phosphorylation motifs. 
Interestingly, the only PKC isozyme identified as a PRMT5-interacting partner from our 
mass spectrometry protein identification studies was PKC iota (PKCɩ), belonging the 
family of atypical PKCs. Furthermore, the motif containing the S15 site bore striking 
similarity to a highly consensus atypical PKC's substrate recognition sequence pattern 
previously identified by another group (C. Wang et al., 2012). Collectively, this argues for 
PKCɩ as a promising candidate for mediating phosphorylation of PRMT5. As proof of 
principle, validation studies to test this notion are outlined in this chapter.  
 
5.2 Results 
5.2.1 Identification of PKCɩ as an interacting partner of PRMT5 
To determine which kinase(s) phosphorylates PRMT5 at S15, we first utilized the 
Human Protein Reference Database (http://www.hprd.org/ PhosphoMotif_finder) to 
predict PKC and PKA as putative kinases related to S15 phosphorylation based on 
consensus sequence phospho-motifs (Figure 22A). To narrow down the top candidate 
kinase, we then identified the isozyme PKCɩ as an interacting partner of PRMT5 based 
on our mass spectrometry studies and further confirmed this interaction using co-
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immunoprecipitation studies in HEK293 and HT29 cells. As shown in Figure 22B, Flag-
WT-PRMT5 co-immunoprecipitated with endogenous PKCɩ under basal and IL-1β-
stimulating conditions, validating the formation of a complex between PRMT5 and PKCɩ.  
 
5.2.2 Knockdown of PKCɩ correlates to decreased serine phosphorylation of PRMT5 and 
disruption of the PRMT5-p65 complex  
Next, we wanted to confirm that PRMT5 serves as a substrate of PKCɩ, and 
hence, we used a pool of shRNA constructs to knockdown the expression of PKCɩ 
concurrent with Flag-tagged WT-PRMT5 (Flag-WT) overexpression in HEK293 cells 
(Figure 23A). These cells were then treated with IL-1β, followed by immunoprecipitation 
of Flag-WT to detect PRMT5 phosphoserine (pSER) levels. As shown in Figure 23B, 
induction of serine phosphorylation of PRMT5 was observed under IL-1β-stimulating 
conditions in the cells co-expressing Flag-WT and shscramble constructs. By contrast, 
the Flag-WT protein purified from shPKCɩ cells showed diminished IL-1β-induced 
phosphorylation, confirming that PKCɩ mediates phosphorylation of PRMT5 in a ligand-
inducible manner. Our next logical step was to examine whether PKCɩ could in turn 
regulate NF-ĸB signaling through disruption of the PRMT5-p65 complex. Stable HEK293 
cells described in Figure 23A were subjected to co-immunoprecipitation. As shown in 
Figure 23C, knockdown of PKCɩ correlated with a disruption of the IL-1β-inducible 
PRMT5-p65 complex formation, similar to that previously observed with the S15A 
mutant (Figure 14).  
 
5.2.3 PKCɩ regulates PRMT5-mediated NF-ĸB activation through S15 phosphorylation  
To further test whether PKCɩ could regulate NF-ĸB activity through 
phosphorylation of PRMT5 at S15, we conducted NF-ĸB luciferase assays using 
HEK293 cells overexpressing vector control, WT-PRMT5 or S15A-PRMT5 constructs 
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with or without depletion of PKCɩ (Figure 23A). As shown in Figure 24A, knockdown of 
PKCɩ correlated with significantly decreased IL-1β-inducible NF-κB activity in vector 
control and WT-PRMT5- overexpressing cells compared to their shscramble 
counterparts. Consistent with our earlier findings, overexpression of the S15A-PRMT5 
mutant significantly attenuated the activation of NF-κB compared to WT-PRMT5. 
Interestingly however, no further decrease in NF-κB activity in the IL-1β-treated S15A-
PRMT5 /shPKCɩ cells was observed, suggesting that blockade of PKCɩ was likely acting 
through the S15 phosphorylation site of PRMT5. We sought to corroborate these 
observations using a selective small molecule PKCɩ inhibitor CRT0066854. We observed 
a similar phenomenon in which CRT0066854 disrupted IL-1β-inducible WT-PRMT5-
mediated activation of NF-ĸB luciferase activity whereas no further decrease in NF-ĸB 
activity was detected in S15A-PRMT5 cells treated with the inhibitor under IL-1β-
stimulating conditions (Figure 24B).  
 
5.2.4 PKCɩ is significantly upregulated in human colorectal adenomas  
PKCɩ has emerged as a bonafide oncogene in several types of cancers. Hence, 
based on the above findings, deregulation of PKCɩ in the context of CRC could be one 
potential mechanism that leads to aberrant phosphorylation of PRMT5 and in turn, 
downstream activation of NF-ĸB. Using an online TCGA-based database we initially 
assessed the relative transcript levels of PKCɩ in CRC tissues and found that in fact, it 
was highly upregulated in Stages I-IV compared to normal patient samples (Figure 25), 
indicating that PKCɩ may potentially have biomarker significance or be an actionable 
target in CRC (http://ualcan.path.uab.edu)(Chandrashekar et al., 2017).  We have 
outlined several validation experiments in the future directions section to address these 




















Figure 22: PKCɩ forms a complex with PRMT5. A. Human Protein Reference Database predicted PKC and PKA phospho-motif in 
position 13-15 of PRMT5. B. Co-immunoprecipitation (IP) experiments, HEK293 and HT29 cells were treated or left untreated with 
IL-1β (10ng/mL) for 1 h, Flag-WT-PRMT5 (Flag-WT) was immunoprecipitated with anti-Flag beads. Samples were then subjected to 
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Figure 23: PKCɩ phosphorylates PRMT5 and regulates formation of PRMT5-p65 complex. A. Establishment of vector control, Flag-
WT-PRMT5 or Flag-S15A-PRMT5- overexpressing HEK293 stable cells with concurrent expression of either shscramble or shPKCɩ 
constructs. Western blot image, probed with anti-PKCɩ, PRMT5, or -actin respectively. B. Detection of PKCɩ-mediated serine 
phosphorylation of PRMT5 using co-immunoprecipitation and western blot analyses. Either HEK293 cells with vector control and 
shscramble, Flag-WT and shscramble or Flag-WT and shPKCɩ were treated with IL-1β or left untreated for 1 h (10 ng/mL). Samples 
were collected and Flag-WT was further immunoprecipitated with anti-FLAG beads and subjected to western analysis using an anti-
phospho-serine motif antibody (pSER). The inputs were probed with anti-PRMT5 or Flag antibody. C. Co-immunoprecipitation (IP) 
experiment, HEK293 cells were treated or left untreated with 10 ng/ml of IL-1β for 1 h, WT-PRMT5 (Flag-WT) or S15A (Flag-S15A) 
was immunoprecipitated with anti-FLAG beads. Samples were then subjected to western blot analysis and probed with anti-p65 














































Figure 24: PKCɩ regulates PRMT5-mediated NF-ĸB activation through S15 
phosphorylation. NF-κB activity was determined by luciferase assay, in established cells 
shown above (Figure 22A). A. NF-κB activity luciferase assay in vector control or cells 
overexpressing WT-PRMT5 (WT) or S15A-PRMT5 with or without knockdown of PKCɩ in 
the presence or absence of IL-1β stimulation. B. NF-κB activity luciferase assay in 
control or cells overexpressing WT-PRMT5 (WT) or S15A-PRMT5 treated with or without 
PKCɩ small molecule inhibitor, CRT0066854 in the presence or absence of IL-1β 
stimulation in HEK293 and C. HT29 cells. The data represent the mean ± SD from three 
independent experiments. #p<0.05 vs. Ctrl+IL-1 β group; **p<0.05 vs. WT+IL-1β group; 
















Figure 25: PKCɩ is significantly upregulated in colorectal cancer patient samples. Upper 
panel, Boxplot showing relative transcript levels of PKCɩ in normal and colorectal 
adenoma human samples based on individual cancer stages. Bottom panel, Log-rank 










Figure 26: Hypothetical model. IL-1β stimulation activates the NF-κB pathway and 
induces PKCɩ-mediated phosphorylation of PRMT5. Phosphorylation of PRMT5 at S15 
elicits formation of the PRMT5-p65 complex and regulates PRMT5-dependent proximal 
promoter occupancy of p65 at target genes. Collectively, these constitute pivotal 
mechanisms by which PRMT5 can fine-tune NF-κB activation and target gene 
expression. Furthermore, S15 phosphorylation mediates IL-1β-induced PRMT5 activity 
and in turn the R30 methylation of p65. These signal-induced effects potentially serve to 











5.3 Summary and Discussion  
Protein kinases belong to one of the largest families of enzymes and are known 
to play key roles in nearly all cellular functions including signal transduction, cell cycle 
regulation, cell division, apoptosis and cell differentiation, among others. Of the 518 plus 
protein kinase genes in the human genome, approximately 372 belong to the class of 
serine/threonine kinases (STKs), some of which are receptors or dual specificity protein 
kinases (tyrosine and serine/threonine) (Roskoski, 2015). Using a combined approach of 
co-immunoprecipitation, mass spectrometry protein identification and PhosphoMotif 
Finder we identified the STK PKCɩ as a potential candidate kinase that catalyzes the 
phosphorylation of PRMT5 at S15. PKCs are widely known as important regulators of 
signal transduction cascades. These isozymes are divided in 3 major subcategories 
based on the signals that activate them such as diacylglycerol (DAG) or calcium ions 
(Ca2+): conventional PKCs (α, βI, βII, and γ) require Ca2+, DAG, and a phospholipid such 
as phosphatidylserine for activation whereas novel PKCs (δ, ε, η, and θ) need DAG, but 
not Ca2+ for activation. PKCɩ belongs to the third class, namely atypical PKCs (Mζ , ɩ / λ), 
which require neither Ca2+ nor DAG for activation. Like many kinase families, PKCs 
share some key conserved structural motifs such as a catalytic domain, activation loop 
and ATP binding domain (Newton, 1995).  
Here, we demonstrated that not only does PRMT5 complex with PKCɩ but 
shRNA-mediated depletion of this kinase corresponded with less IL-1β-inducible serine 
15 phosphorylation of PRMT5. Furthermore, using luciferase assays, we showed that 
knockdown or pharmacological inhibition of PKCɩ could impair transactivation of p65 in a 
phosphoPRMT5-dependent fashion, indicating that PKCɩ may be acting upstream of 
both PRMT5 and NF-ĸB. Thus, not only have we established a novel link between PKCɩ, 
phosphorylation of PRMT5 at S15 and NF-κB activation, but this discovery may have 
implications in cancer. PKCι has been characterized as an oncogene and is implicated in 
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the initiation and progression of colitis-associated colon cancer via regulation of 
epithelial cell integrity and polarity (Calcagno et al., 2011). Moreover, mutations and 
genetic alterations of PKCι are often detected across various cancer types including 
ovarian and breast cancer, making it a highly attractive therapeutic target (Nanos-Webb 
et al., 2016; Paul et al., 2014). PKCι upregulation has also been shown to activate 
pathways involved in certain hallmarks of cancer including proliferation, anchorage-
independent growth and epithelial to mesenchymal transition (EMT) (Gunaratne et al., 
2013).  
Interestingly, a few accounts linking PKCɩ and NF-κB have been documented 
and enhanced expression of PKCɩ was shown to protect cancer cells from apoptosis by 
activating NF-κB, although the exact underlying mechanisms are still unclear (Parker et 
al., 2014). For instance, in MDA-MB-468 breast cancer cells, cytokine-mediated 
activation of NF-κB signaling was shown to promote the association of PKCɩ with IKKβ 
resulting in nuclear translocation of p65 (Paul et al., 2014). Similarly, in Th2 cells, PKCι, 
whose levels were increased during Th2 differentiation, was shown to activate NF-κB 
through its complex with IKKβ (Martin et al., 2005; Yang et al., 2009). Two separate 
studies defined a novel pathway for the activation of NF-κB involving PKCɩ, p62 and 
IKKβ in which expression of a dominant-negative mutant PKCɩ impaired RIP-stimulated 
NF-κB by disrupting the association between RIP, p62 and IKKβ (Diaz-Meco et al., 
2012).  Collectively, these studies suggest that the role of PKCɩ in activation of NF-κB is 
perhaps mediated by other cellular signaling factors.  Of great functional relevance in 
this regard is our finding that disruption of PKCɩ-mediated phosphorylation of PRMT5 
could significantly impair IL-1β-stimulated activation of NF-κB. Moreover, in cells 
expressing the S15A-PRMT5 mutant, inhibition of PKCɩ had negligible effects, strongly 
suggesting that activation of NF-κB by PRMT5 was mediated at least in part by this 
phosphorylation event.  
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Our data presents a complex picture which involves a signaling cascade of 
interactions between these important molecules. However, signal transduction events 
can be inherently complicated, and our data raises several questions that remain to be 
experimentally tested. First, we acknowledge that kinases may phosphorylate more than 
one site on their substrates and thus we cannot exclude the possibility that PKCɩ may 
phosphorylate other sites on PRMT5 yet to be identified. Furthermore, there may be 
cross talk between S15 phosphorylation and other PTMs on PRMT5 which may 
concertedly play a role in its activation of NF-κB. These are possibilities we would like to 
ultimately explore. Second, we have shown that PRMT5 complexes with and is a 
substrate of PKCɩ, however, the intricacies of these associations and their relation to p65 
require further investigation. For instance, our co-immunoprecipitation studies showed 
that the complex between PRMT5 and p65 can be enhanced by IL-1β whereas 
formation of the PRMT5/PKCɩ complex remained consistent before and after IL-1β 
stimulation. Interestingly however, knockdown of PKCɩ diminished the IL-1β-induced 
phosphorylation of PRMT5, suggesting that other factors are likely at play. We propose 
that one possibility is that instead of modulating the complex between PRMT5 and PKCɩ, 
IL-1β may trigger a change in the activation state of PKCɩ. In turn, activated PKCɩ 
promotes phosphorylation of PRMT5, facilitating a stronger complex between PRMT5 
and p65. To test these notions, we will conduct future studies to determine whether IL-1β 
induces phosphorylation of PKCɩ at sites known to be involved in its activation. This is in 
keeping with a previous study described by the LaVallie group in which they showed 
that IL-1β treatment of chondrocytes in culture resulted in rapidly increased 
phosphorylation of another atypical PKC isozyme, namely PKCζ (LaVallie et al., 2006).  
Next, using a combination of co-immunoprecipitation and western blot 
approaches, we will probe whether knockdown of PKCɩ disrupts the PRMT5/p65 
complex as well as the R30 methylation status of p65. In terms of understanding the 
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spatiotemporal dynamics of this signaling cascade, we will also conduct co-
immunoprecipitation studies within different cell fractions to determine where this critical 
PKCɩ/PRMT5/NF-κB complex is formed. Finally, considering the afore-mentioned 
reports, it will be interesting to investigate whether in our system a similar association 
between PKCɩ and other components of the NF-κB pathway such as IKKβ exists under 
IL-1β-stimulating conditions. Taken together, these experiments will provide a more 
detailed and mechanistic depiction of these complex signaling relationships.  
 
5.4 Concluding Remarks  
We have identified PRMT5 as a novel substrate of the oncogene PKCɩ. 
Moreover, we demonstrate that PKCɩ serves as an important signaling component of IL-
1β-induced and PRMT5-mediated activation of NF-κB, an effect blocked by knockdown 
or selective inhibition of PKCɩ. Collectively, these studies suggest that the cancer-
associated role of PRMT5 may in part be linked to its functional interaction with certain 
growth promoting proteins, including PKCɩ and NF-κB. We posit that this in turn 
influences its biological activities in such a way to favor hallmark characteristics of 
cancer including invasiveness, cell growth and survival. To this end, further experimental 
studies are needed to validate these latter points. Specifically, we will determine whether 
a corresponding reduction in the migratory, proliferative and anchorage-independent 
growth of CRC cells is observed upon knockdown or inhibition of PKCɩ, similar to the 
effect of overexpressing the S15A mutant of PRMT5 (Chapter 4). Likewise, we would 
expect an overlap in the subset of NF-κB target genes downregulated by PKCɩ depletion 
and S15A-PRMT5 overexpression. In conclusion, our data provides the basis for 
exploiting the therapeutic potential of disrupting the PKCɩ/PRMT5/NF-κB signaling axis in 





CHAPTER 6: CONCLUDING DISCUSSION 
6.1 Challenges in the clinical management of CRC 
CRC remains one of the leading causes of cancer-related deaths worldwide. 
Although significant progress has been made in its clinical management, several 
challenges hinder the overall effectiveness of current treatments. For instance, surgery 
remains the most effective treatment for early-stage CRC, however, a significant fraction 
of patients present with advanced or metastatic disease at the time of diagnosis and of 
these, only 10-25% are resectable. Hence, aggressive combination chemotherapy has 
become the mainstay for disease management. Currently, FOLFIRI and FOLFOX in 
combination with either cetuximab (anti-EGFR) or bevacizumab (anti-VEGF) are used as 
first-line treatments. Unfortunately, chemotherapeutic resistance remains a major 
impediment and hence, many patients with advanced CRC may not experience 
considerable clinical benefit from these treatment combinations. Moreover, many 
patients experience toxic reactions such as nausea, vomiting, diarrhea, neuropathy, hair 
loss and increased risk of infections, resulting in treatment withdrawal or suboptimal 
dosing which can severely hamper treatment efficacy.  
Over the past decade, research efforts have shifted towards identifying more 
reliable and validated therapeutic targets that are likely to have the greatest clinical 
outcome while minimizing adverse effects. To this end, molecular profiling and mutation 
analyses have become critical to CRC treatment individualization, facilitated by rapid 
advances in genomic, transcriptomic and proteomic technologies (Tran et al., 2015). 
Discoveries from these approaches have fueled the development of novel drug targets 
and new treatment strategies. However, translation of these findings into routine clinical 
practice has been limited due to factors such as poor reproducibility in preclinical animal 
experiments and an overall lack of models that accurately predict clinical benefit. Going 
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forward, it will be imperative to establish more robust preclinical models that monitor 
drug responsiveness signatures in concert with molecular categorization of patient 
tissues. Additionally, a better understanding of the tumor microenvironment including the 
interaction between cancer cells and the host immune system should be considered 
when developing new therapies. These approaches will become essential to guiding 
clinicians to make more informed treatment decisions, including optimal sequential or 
combinatorial use of selected agents.  
 
6.2 Key points for consideration  
Phosphorylation-site analyses can provide important and definitive information on 
functional relationships between signaling proteins. In some phosphoregulation 
analyses, mutation of phosphorylation residues to generate “phosphomimetics” has 
become common in an attempt to study the constitutively phosphorylated state of the 
protein. In this approach, serine residues are typically mutated to aspartic (S-to-D) or 
glutamic acid (S-to-E). There are several limitations to this approach. First, if the 
phosphorylation site serves as a recognition signal for an adaptor protein (e.g., 14-3-3), 
phosphomimetic mutants will not bind to the adapter protein. One of the primary 
functions of adaptor proteins is to sequester and position client molecules to interact with 
their binding partners. Hence, one can speculate that in our case, a phosphomimetic 
mutant of PRMT5 may impair its ability to bind to a potential adaptor protein and in turn 
disrupt its complex with p65. A second limitation is the discrepancy in the negative 
charge introduced by the aspartate or glutamate residues and the phosphorylated serine 
at physiological pH which tend to be quite different.  
Moreover, compared to the negatively charged aspartate or glutamate residues, 
the relative size of the ionic shell produced by a phosphate group creates a very different 
chemical environment and thus, phosphomimetic mutations often fail to recapitulate the 
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changes to a protein conferred by phosphorylation. Consequently, although there are 
examples in which phosphomimetic substitutions have been informative, the general 
effects of these mutations are often not easily interpretable.  
 
6.3 Future Directions  
Based on the exciting work presented in this thesis as summarized in Figure 26, 
we can infer that phosphorylation of PRMT5 at S15 is critical to the regulation of the 
PRMT5/NF-κB signaling axis (Chapter 3) and mediates some of the hallmark cancer-
associated phenotypes exerted by PRMT5 in CRC (Chapter 4). Moreover, from our 
kinase identification studies in Chapter 5, PKCɩ emerges as a critical upstream regulator 
of both PRMT5 and the NF-κB pathway. Altogether, these findings suggest that 
pharmacological disruption of this axis using PKCɩ inhibitors could serve as the basis for 
new therapeutics that impede CRC progression. This opens up several avenues of 
exciting future studies. Currently, there are only a limited number of pan inhibitors on the 
market against PKCs but to our knowledge, few to none with high selectivity for PKCɩ. 
Hence, one of our immediate goals is to identify candidate PKCɩ inhibitors with the 
possibility of generating more efficacious derivatives of the most promising compounds. 
Initially, we will utilize a combined approach that includes structural docking analyses 
and in vitro screens of compound libraries to identify small molecule inhibitors with high 
selectivity for PKCɩ over other PKC isozymes. Next, we will test the efficacy of top 
compounds in impeding CRC growth using complementary cell-based and animal-based 
models of disease such as 3-D cultures, xenograft and orthotopic mouse models. 
Finally, to establish whether our lead compound selectively disrupts the PRMT5/NF-κB 
axis in our in vivo models, we can probe the mouse tissue to see if we observe a 
correlative decrease in the levels of S15 phosphorylated PRMT5, p65 dimethylation 
accompanied by a resultant decreased expression of relevant NF-κB target genes.  
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Another important area of research to pursue involves elucidating the structural 
intricacies of the PRMT5/p65/PKCɩ complex. First, we will undertake detailed co-
immunoprecipitation-based mapping of the interaction domains between the three 
proteins to determine if they directly bind and if so, which critical residues are involved in 
their interaction. This data will be valuable for informing molecular dynamics simulation 
(MDS) studies for determining potential binding “hotspots”, which are defined as a 
cluster of residues that makes a major contribution to the binding free energy (Brinda et 
al., 2005). Intriguingly, previous reports have shown that phosphorylation sites are 
frequently located on binding interfaces which can then serve as important hotspots that 
modulate the strength of protein-protein interactions by causing significant changes in 
binding energy (Nishi et al., 2011). Hence, using the MDS platform, it would be 
interesting to determine if phosphorylation of PRMT5 at S15 serves as one such hotspot 
and investigate how it might mediate the protein-protein interactions previously 
characterized by us. These experiments may necessitate co-crystallization of PRMT5 
with p65 and PKCɩ.  
Furthermore, we have shown for the first time that S15 phosphorylation 
constitutes an important positive regulator of the IL-1β-inducible methyltransferase 
activity of PRMT5. Interestingly, our findings stand in contrast to a previous study that 
identified tyrosine phosphorylation (Tyr297, Tyr304, Tyr307) of PRMT5 by mutant Jak2 
as playing an inhibitory role on PRMT5’s activity. It is important to note that these studies 
were carried out under very different cellular contexts. Whether these tyrosine 
phosphorylation events are induced by stimuli other than IL-1β is currently unknown 
since we did not detect these modifications in our mass spectrometry analyses carried 
out using IL-1β-treated cells. Hence, the previous functional implications of these 
particular tyrosine PTMs may not necessarily be relevant in our system. However, it 
would be interesting to compare the differential effects conferred by S15 phosphorylation 
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versus tyrosine phosphorylation purely at the structural level. This may provide deeper 
molecular insight into the unique function of distinct PTMs in regulating PRMT5 
enzymatic activity through potentially divergent conformational changes.  
Finally, we acknowledge that CRC like other cancers, is a highly heterogeneous 
disease and the “curative” potential of a single targeted therapeutic agent would be an 
unrealistic expectation. Thus, continued efforts to determine the optimal combinations of 
compounds and/or drugs for the treatment of CRC patients are needed. Along these 
lines, we will consider the combined efficacy of our lead PKCɩ inhibitor with other 
mainstream chemotherapeutic regimens and/or targeted agents. Indeed, some of these 
approved agents (e.g., anti-EGFR drugs) target other pathways in which PRMT5 has 
been implicated. However, we are yet to determine if the role of S15 phosphorylation 
extends beyond PRMT5-mediated activation of NF-κB or if methylation of other PRMT5 
substrates plays a role in CRC progression. If these pathways or substrates are proven 
to be important in our models, more detailed studies can be conducted to determine the 
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Appendix B. List of qPCR primers 
Gene Name  Primer  Lab Record  Primer Sequence Used  
GAPDH Forward F326 5’-CCATCACCATCTTCCAGGAGCG-3’ 
  
 Reverse   R468 5’-AGAGATGATGACCCTTTTGGC-3’  
 
IL8 Forward F139 5’-TCCTGATTTCTGCAGCTCTGT-3’ 
 
 Reverse   R245 5’-AAATTTGGGGTGGAAAGGTT-3’ 
 
CCL20 Forward F112 5’-GTGCTGCTACTCCACCTCTG-3’ 
 





















Appendix C. List of primers used for site mutagenesis of PRMT5 
Primer Name  Primer  Primer Sequence Used for Mutagenesis  
PRMT5-S15A-
PRMT5  
Forward 5'-GGAGCCGCGTGGCCAGCGGGAGG-3'  
 
 Reverse   5'-CCTCCCGCTGGCCACGCGGCTCC-3'   
 
PRMT5-E444D Forward 5’-CACTCAGGCGACAAATCATTGTCAGCAAATGAGCCC-3’ 
 





















Appendix D. Ingenuity Pathway Analysis Networks. 
IPA representative networks showing genes regulated by S15A-PRMT5 with NF-κB as 
























Appendix E. Full list of genes downregulated by the S15A-PRMT5 mutation. Fold 
change is represented as S15A-PRMT5 +IL-1β/WT+IL-1β ≤ 0.5 
 
ACCESSION NO. TargetID S15A-PRMT5 +IL-
1β/WT+IL-1β 
NM_001115.1 ADCY8 0.45 
NM_014391.2 ANKRD1 0.38 
NM_020373.2 ANO2 0.15 
XR_041624.1 C10ORF85 0.36 
XR_041485.1 C13ORF29 0.27 
XM_001726191.1 C19ORF29OS 0.00 
NM_178342.2 C3ORF35 0.50 
NM_018452.3 C6ORF35 0.32 
NM_145028.3 C6ORF81 0.16 
NM_152786.1 C9ORF43 0.33 
NM_001742.2 CALCR 0.24 
NM_175931.1 CBFA2T3 0.28 
NM_138414.1 CCDC101 0.41 
NM_015603.1 CCDC9 0.48 
NM_004591.1 CCL20 0.37 
NM_207007.2 CCL4L2 0.47 
NM_145057.2 CDC42EP5 0.41 
NM_000735.2 CGA 0.33 
NM_000737.2 CGB 0.45 
NM_024111.2 CHAC1 0.00 
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NM_015557.1 CHD5 0.27 
NM_024944.2 CHODL 0.47 
NM_138429.1 CLDN15 0.49 
NM_080645.2 COL12A1 0.22 
NM_002089.3 CXCL2 0.29 
NM_016229.3 CYB5R2 0.36 
NM_000779.2 CYP4B1 0.31 
NR_024064.1 DAD1L 0.39 
NM_006557.4 DMRT2 0.28 
NR_024595.1 DNM1P35 0.06 
NM_133637.1 DQX1 0.37 
NM_004428.2 EFNA1 0.48 
NM_007036.2 ESM1 0.22 
NM_153606.2 FAM71A 0.50 
NM_001012426.1 FOXP4 0.06 
NM_000148.2 FUT1 0.35 
NM_002068.1 GNA15 0.40 
XM_935238.1 GOLGA8F 0.45 
BX109627 HS.130639 0.46 
AI801879 HS.144030 0.14 
BU633914 HS.25555 0.27 
AK026734 HS.287720 0.34 
AF339771 HS.344872 0.19 
CD695721 HS.538157 0.00 
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AI253067 HS.541845 0.20 
U10515 HS.544238 0.46 
AI628074 HS.545238 0.13 
NM_130770.2 HTR3C 0.28 
NM_172200.1 IL15RA 0.17 
NM_001012633.1 IL32 0.49 
NM_000564.2 IL5RA 0.50 
NM_000584.2 IL8 0.48 
NM_002195.1 INSL4 0.30 
XM_934728.1 KIAA0565 0.09 
NM_138343.2 KLC4 0.02 
NM_002774.3 KLK6 0.34 
NM_004139.2 LBP 0.29 
NM_001010939.1 LIPJ 0.18 
NM_033029.2 LMLN 0.15 
XM_001724965.1 LOC100129268 0.13 
XM_001716704.1 LOC100130288 0.15 
XM_001718675.1 LOC100130705 0.50 
XM_001714361.1 LOC100131999 0.18 
XR_038987.1 LOC100132496 0.37 
XM_001724630.1 LOC100132716 0.05 
XM_001726146.1 LOC100132839 0.06 
XM_001721522.1 LOC100134009 0.18 
XM_001720931.1 LOC100134041 0.14 
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XM_001715304.1 LOC100134081 0.00 
XM_001721704.1 LOC100134170 0.19 
XM_001714134.1 LOC100134499 0.00 
NM_178514.3 LOC283487 0.26 
XM_944838.2 LOC285733 0.27 
XM_939888.1 LOC339742 0.49 
XM_370865.4 LOC388122 0.23 
XM_374766.2 LOC399715 0.11 
XM_495854.3 LOC440013 0.10 
XM_001717499.1 LOC642076 0.04 
NR_024495.1 LOC642826 0.40 
XM_927139.1 LOC643869 0.14 
XM_933938.2 LOC643872 0.38 
XM_928663.1 LOC645649 0.03 
XR_037491.1 LOC646808 0.46 
XM_943707.1 LOC649431 0.33 
XM_941853.1 LOC652416 0.00 
XM_928640.1 LOC653651 0.39 
XM_001126803.1 LOC728185 0.36 
XR_015405.1 LOC728895 0.43 
XM_001130993.1 LOC729675 0.23 
XM_001714434.1 LOC730376 0.40 
NM_002343.2 LTF 0.01 
NM_012323.2 MAFF 0.44 
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NM_005204.2 MAP3K8 0.39 
NM_052858.3 MARVELD3 0.33 
NM_033290.1 MID1 0.33 
NR_030209.1 MIR518E 0.31 
NM_173855.3 MORN3 0.40 
NM_013404.3 MSLN 0.21 
NM_003828.2 MTMR1 0.45 
NM_001005474.1 NFKBIZ 0.47 
NM_001080379.1 PACRG 0.01 
NM_000438.3 PAX3 0.27 
NM_003706.1 PLA2G4C 0.41 
NM_002658.2 PLAU 0.44 
XM_940486.1 PLEKHA2 0.26 
NM_014330.2 PPP1R15A 0.46 
NM_022114.2 PRDM16 0.11 
NM_000963.1 PTGS2 0.32 
NM_000963.1 PTGS2 0.40 
NM_001024455.2 RGAG4 0.43 
NM_184237.1 RNPC2 0.48 
NM_001007098.1 SCP2 0.40 
NM_000450.1 SELE 0.22 
NM_013386.3 SLC25A24 0.41 
NR_003237.1 SNORD113-9 0.34 
XM_291729.7 TAF3 0.38 
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NM_031898.1 TEKT3 0.16 
NM_001001524.2 TM6SF2 0.10 
NM_001097620.1 TMEM184A 0.08 
NM_002160.2 TNC 0.45 
NM_002160.1 TNC 0.44 
NM_006290.2 TNFAIP3 0.28 
NM_001561.4 TNFRSF9 0.50 
NM_033229.2 TRIM15 0.41 
NM_020810.2 TRMT5 0.21 
NM_001080419.1 UNK 0.50 
NM_030570.2 UPK3B 0.39 
NM_001078.2 VCAM1 0.15 
NM_206923.1 YY2 0.30 












Appendix F. Status of frequently mutated genes identified in CRC cell lines. SNV: 
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